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Inspiration and Dreams
“The best and most beautiful things in the world cannot be seen, nor touched…but are felt
in the heart.” Helen Keller (1880-1968)

“The future belongs to those who believe in the beauty of their dreams.” Eleanor
Roosevelt (1884-1962)

It has always been a dream of mine to make a memorable contribution to this life’s
journey. The notable and excellent quotes above best describe what this particular research
has meant to me. I have always wanted to use what knowledge and experiences I have
attained in school and life, to contribute to the well being of others in need, hence this
research helped fulfill a sense of purpose and contribution as part of my life’s journey. So
to be able to follow one of my dreams and finish this most intriguing research, which may
someday benefit society, has been a great honor and experience for me. Several
individuals close to me are primarily responsible for inspiring me to finish this graduate
school and I would like to recognize them. The person most responsible for me finishing
this graduate work is my mother, Setsuko aka “Momason”, whom I owe sincere thanks for
her constant words of motivation and encouragement.
Another individual who also inspired me is our daughter, Christine, who through
her years of a serious medical ailment has shown me what real strength, determination, and
the passion to succeed in life are all about. She will graduate from college Virginia
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Commonwealth University (VCU) in the coming year and is already looking at
professional or graduate school; which is a remarkable feat given what she had gone
through for many years. And many accolades to her brother Bryan, who has shown me
what sibling love and support are all about, as he stood strongly by his sister and family.
We are very blessed to have two wonderful children to watch grow up, have their own
dreams and to make contributions to their journey in life. I end with the encouragement to
others, to follow your dreams and use your instincts and heart to help you make good
choices in life. If you have a passion for something, pursue it vigorously, and give it your
best efforts. Isn’t that what life and this part of our journey are truly all about?
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Abstract

INVESTIGATION OF INOSINE AND HYPOXANTHINE AS BIOMARKERS OF
CARDIAC ISCHEMIA IN PLASMA OF NON-TRAUMATIC CHEST PAIN PATIENTS
AND A RAPID ANALYTICAL SYSTEM FOR ASSESSMENT
By Don E. Farthing, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2008
Major Director: H. THOMAS KARNES, Ph.D.
PROFESSOR, DEPARTMENT OF PHARMACEUTICS

Each year in the U.S., approximately 7-8 million patients with non-traumatic chest
pain visit hospital emergency departments (ED) for medical evaluation. It is estimated that
approximately 2-5% of these patients are experiencing acute cardiac ischemia, but due to
the shortcomings of current test methods, they are incorrectly diagnosed and discharged
without appropriate treatment provided, thus leading to poor patient outcome and potential
medical malpractice litigation. The goals of this research were to evaluate plasma samples

xxvi
for potential biomarker(s) of acute cardiac ischemia prior to heart tissue necrosis, and to
ultimately develop a rapid method for detection of the potential biomarker(s) in human
plasma. Initial experiments were performed using the mouse model, with subsequent
evaluations on human plasma samples using high performance liquid chromatographic
ultraviolet detection (HPLC-UV). The final phase of this research involved the
development of a rapid luminometer test method (<10 min analysis time objective) to be
potentially used in the clinical laboratory environment.
An HPLC-UV detection method was developed and utilized for inosine,
hypoxanthine and other adenosine triphosphate (ATP) catabolic by-products in KrebsHenseleit (Krebs) buffer solution, with analysis on perfusate samples from isolated mouse
hearts undergoing 20 min acute global ischemia. The HPLC-UV method was modified for
subsequent use on human plasma samples, obtained from hospital emergency department
(ED) patients presenting with non-traumatic chest pain (potential acute cardiac ischemia)
and from healthy normal individuals. The HPLC-UV (component quantification) and
HPLC-MS (component identification) test methods utilized C18 column technology,
mobile phases consisting of aqueous trifluoroacetic acid (0.05% TFA in deionized water
pH 2.2, v/v) and methanol gradient to achieve component separation, with both utilizing
simple sample preparations (e.g. direct injection of Krebs perfusate samples and
centrifugal membrane filtration on plasma samples).
Results of the animal experiments using isolated mouse hearts undergoing 20 min
acute global ischemia demonstrated significant levels of endogenous inosine effluxed from
the heart tissue, indicating its use as a potential candidate biomarker of acute cardiac

xxvii
ischemia. The HPLC results from human plasma representing ED non-traumatic chest
pain patients demonstrated elevated levels of inosine (hypoxanthine precursor) and
significant levels of hypoxanthine, which provided additional support for the use of these
candidate biomarker(s) as a potential diagnostic tool for the initial acute cardiac ischemic
event, prior to heart tissue necrosis.
The final phase of this research focused on the development of a rapid, simple and
sensitive chemiluminescence test method. Using a microplate luminometer with direct
injectors and continuous mixing, the measurement of inosine and hypoxanthine in human
plasma was achieved for healthy normal individuals and on patients with confirmed acute
MI, with an analysis time of less than 5 minutes. The utility of this rapid luminescence
technique would be the potential use at point-of-care (POC) services (e.g. hospital clinical
laboratory or emergency medical services) as part of the initial ED treatment protocol on
patients presenting with non-traumatic chest pain and signs/symptoms of acute myocardial
ischemia or acute MI.
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CHAPTER 1. Background and Significance
1.1

Introduction and Request for Additional Biomarkers
Cardiovascular diseases (e.g. acute myocardial infarction (MI)) are the leading

cause of mortality in the world [Naudziunas et al., 2005; Okrainec et al., 2004; Dorner et
al., 2004, AHRQ, 2000]. Each year in the US, approximately 7-8 million patients present
with non-traumatic chest pain and seek emergency medical treatment [Morrow et al.,
2007]. Current emergency medical evaluation on these patients suspected of having acute
MI includes obtaining patient history, signs and symptoms, vitals, electrocardiogram
(ECG) and blood evaluation for specific cardiac biomarkers [Beyerle, 2002; A.D.A.M.
Inc., 2005; Lees, 2000]. However, the percent diagnostic accuracy of acute MI when using
patient signs and symptoms, ECG and c-troponin is only approximately 50%. With the
addition of the recently FDA cleared albumin cobalt binding assay, the diagnostic accuracy
improves to approximately 70%; hence the need for additional research for biomarkers of
acute cardiac ischemia to further improve patient diagnostic accuracy is important.
The hospital emergency department blood evaluation determines levels of several
specific endogenous cardiac protein biomarkers (e.g. cardiac troponin I and T (cTnI,
cTnT), creatine kinase-MB (CK-MB) isoform, and myoglobin). However, these protein
biomarkers are indicative of cardiac tissue necrosis, and are typically detected hours after
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the acute cardiac event (infarct), and not at the time of acute cardiac ischemia, which may
include angina (stable or unstable, but non-necrotic).
One recent published scientific editorial requested the need for early onset
biomarkers of acute cardiac ischemia prior to cardiac tissue necrosis [Morrow et al., 2003].
Ideally, these early onset biomarkers would aid emergency medical services (EMS)
personnel in the rapid diagnosis and treatment of initial acute cardiac ischemia (potentially
acute MI), thus increasing the survival rate of acute MI victims every year. One research
group [Bhagavan et al., 2003] addressing the scientific editorial request, describes a blood
measurement for ischemia modified albumin (IMA), which appears at an elevated level in
the bloodstream from patients undergoing an ischemic cardiac event; however the author’s
state that the colorimetric test would not discriminate between cardiac ischemic patients
with and without acute MI (e.g. angina), and recent clinical evaluations of the test assay
have reported significant false positive results.
Table 1 depicts the US and world wide heart attack (HA) statistics compiled in
2002 and clearly demonstrates the critical need for additional endogenous biomarkers of
early onset cardiac ischemia [World Health Organization (WHO), 2002]. As can be seen
from the WHO heart attack statistics table, approximately 24 individuals die every minute
in the world from heart attacks, with many individuals waiting more than two hours before
seeking medical attention. The American Heart Association cites that approximately 7580% of the heart attacks occur at home, with up to 95% dying before ever reaching a
hospital [American Heart Association Statistics, 2007]. Thus, the need for continued
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Table 1. World Health Organization (WHO) 2002 Heart Attack Statistics.

Heart Attack (HA) Statistics (WHO 2002)

Heart Attack (HA) Statistics (WHO 2002)
Worldwide statistics

US statistics

~32 million worldwide heart
attacks each year

~1.1 million US heart
attacks each year

• ~50% HA victims wait >2 hrs. before
getting help
• ~40-75% die before reaching the hospital
• ~12.5 million HA are fatal each year

~24 HA victims die every minute

• ~650,000 HA are first events
• ~450,000 HA are recurrences
• ~511,000 HA are fatal each year

• ~47% HA victims die every day or
• ~1,400 HA victims die every day or
• ~58 HA victims die every hour or
• ~1 HA victim dies every minute
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additional research for additional biomarkers of acute cardiac ischemia is critical in
addressing the health care community requests [Maisel et al., 2005, Morrow et al., 2007,
Apple et al., 2005].
1.2

Biomarkers, Use and Requirements
Biomarker is a term defined by the U.S. Food and Drug Administration (FDA) as

“a characteristic that is objectively measured and evaluated as an indicator of normal
biologic or pathogenic processes or pharmacological responses to a therapeutic
intervention.” [FDA, Rockville, USA]. Examples of current biomarkers in human blood
that are commonly used to aid in diagnosis and treatment of medical conditions are
hemoglobin-A1c and glucose levels for diabetes, cardiac protein troponin I (cTnI) and
creatine-kinase MB (CK-MB) isoenzyme (both being very specific to cardiac tissue) for
acute MI, and hormone human chorionic gonadotropin (hCG) for pregnancy testing
[Bloom et al., 2003].
A biomarker is classified as a surrogate endpoint, which is an objective
characteristic, intended to substitute for a clinical (and sometimes subjective) endpoint
[Biomarker World Congress 2007, USA]. For example, one clinical endpoint for acute MI
can be how the person feels (e.g. chest pain, nausea, fatigue), which can be subjective and
caused by other various medical conditions (Table 2). However, using current biomarker
surrogate endpoints for acute MI (elevated plasma concentrations of cardiac proteins
myoglobin, CK-MB and cTnI or cTnT) significantly improves patient diagnostic accuracy,
and may led to prompter emergency medical intervention (treatments), and improved
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Table 2. Listing of various medical conditions causing non-traumatic chest pain other than
acute cardiac ischemia and acute MI. Information tabulated from Prehospital Emergency
Care, 7th Edition, Mistovich et al., 2004.
Condition

Symptom profile

Gastroesophageal reflux

Dull to sharp chest pain, chest pressure, nausea and vomiting

Acid Reflux

Dull chest pain, chest pressure, heartburn

Angina

Breathlessness or choking feeling, heavy weight or tightening
across the upper chest

Musculoskeletal

Sharp pains confined to a specific area of the chest

Pneumonia

Sharp pain on side of the chest, anxiety, rapid breathing

Aortic Dissection

Ripping or tearing pain, shortness of breath, abdominal pain,
fainting

Nerve Impingement

Shooting, burning pain, numbness

Pulmonary Embolus

Shortness of breath, rapid breathing and sharp pain in the mid
chest

Spontaneous Pneumothorax

Shortness of breath, sharp chest pain, rapid heart rate,
dizziness

Acute Pericarditis

Sharp or stabbing pain in the mid chest

Heartburn

Burning pain in chest, nausea, vomiting

Asthma

Shortness of breath, wheezing or cough

Anxiety

Palpitations, sweating, muscle tension, fatigue

Peptic Ulcer

Abdominal pain below the sternum, nausea, vomiting
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patient outcomes. A “routine biomarker” is currently defined as the use of FDA approved
commercial kits and assays for testing in diagnostic labs (e.g. cTnI and CK-MB are routine
biomarkers used as indicators of acute MI). A “novel biomarker” is currently defined as a
non-routine kit or assay “for research only,” and typically utilized in biotechnology
(discovery) or academic environments [Biomarker World Congress 2007, USA].
An example of how one recent novel biomarker progressed into a routine
biomarker is the current use of ischemia modified albumin as an indicator for acute cardiac
ischemia. A detailed description of this test will be later described in Section 1.4. Many
years of research (>10 years) went into the development of using ischemia modified
albumin as a potential biomarker of acute cardiac ischemia, with the first US patent being
filed in 1991 [Bar-Or et al, 1991], and subsequent FDA clearance for use 12 years later in
2003 (assay was initially called albumin cobalt binding (ACB) and is currently called
ischemia modified albumin (IMA)).
Some considerations are important in the discovery and development of a potential
endogenous plasma biomarker. If the biomarker is endogenous to plasma, it may exhibit
circadian fluctuations in basal concentrations levels. For example, C-reactive protein
(CRP), which is currently recognized as an endogenous plasma biomarker of
inflammation, has both seasonal and diurnal variation in a patient’s basal plasma
concentration. Thusly, if measuring CRP, it would have been important to document the
date and time of the blood sample draw, as it may have affected the diagnostic
interpretation of the laboratory sample results.
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Several other important biomarker considerations are determining (or sourcing
from reported literature) the half-life and whether co-existing medical conditions (e.g.
kidney disease) affects the plasma biomarker concentrations. Knowing the component
half-life is important as some plasma biomarkers have very short half-lives (e.g. inosine is
less than 5 minutes), while others may have longer half-lives (e.g. cTnI can be detected for
several days). It is well documented that patients diagnosed with chronic renal failure
typically have high plasma levels of many constituents due to their kidney clearance
problems. Thus the need for their frequent hemodialysis treatments, and potential errors in
interpreting their plasma test results. Typically, plasma biomarker discoveries involve the
use of techniques such as LC-MS, with subsequent clinical use of the FDA cleared
biomarker typically employing automated clinical platforms utilizing immunoassay or
enzymatic techniques [Biomarker World Congress, 2007].
Use of endogenous plasma biomarkers as medical diagnostic tools is a relatively
new field in industry, as compared to discovery and development of drugs (pharmaceutical
industry); however both industries are regulated by the US FDA. One important difference
between these two regulated industries is that when using endogenous plasma biomarkers
as a diagnostic tool, it is important to demonstrate the proof-of-concept (proof-of-biology)
on how the level of the biomarker relates to the associated disease condition. Approval of
pharmaceutical drugs typically requires clinical studies demonstrating patient safety and
efficacy evaluations; however the exact biological mechanism-of-action is not always
known (e.g. some cancer drugs are known to be efficacious, without fully understanding
the exact mechanism of action).
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For medical diagnostic biomarkers, it is important to link the biomarker with the
disease condition and patient clinical outcome. This requires either published scientific
knowledge or demonstration of the mechanism-of-action on how the endogenous plasma
biomarker change is associated with the disease condition. For example, the human
plasma level of cTnI is normally found at <0.05 µg/L in healthy normal individuals, but
under conditions of acute cardiac MI, the levels of cTnI are significantly elevated (≥0.05
µg/L) due to the affected heart tissue (necrotic) being diffused into the bloodstream, which
causes the increase in the concentration of cardiac troponins (e.g. cTnI, cTnT). Chapter 2
of this research utilizes the mouse model to demonstrate the proof-of-concept (proof-ofbiology) that one ATP catabolic by-product, inosine, may be a potential candidate
biomarker of acute global cardiac ischemia.
Current requirements for proposed biomarker test methods to address are
component specificity and sensitivity. Specificity is a term defined as the uniqueness of
the biomarker for the disease or condition for which it will be used to aid in patient
diagnosis. Specificity is the test procedure’s ability to measure a negative response
(minimize false positives). Conversely, sensitivity is a term defined as the ability of a test
procedure to measure a positive response. For many analytical measurements, sensitivity
is directly related to the method detection limit and slope of the detector response relative
to the concentration level of the analyte (e.g. low method detection limit and large positive
slope typically indicates a sensitive test method). The test method detection limit is an
important parameter to determine and is defined as the ratio of analyte signal to matrix and
instrument electronic noise. The goal of a good biomarker test method is to possess both a
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high specificity (reduce the number of false positive results) and high sensitivity (reduce
the number of false negative results). Insufficient evaluation of these criteria may lead to
poor patient outcomes (e.g. false positives may lead to erroneous medical treatment(s) and
psychological stress and false negatives may lead to poor patient prognosis, especially for
cancer patients).
As the field of medical diagnostics and use of biomarkers continues to grow, it is
important to standardize the method development approach and validation requirements of
biomarker assays. In recent years, representatives from pharmaceutical, biotechnology,
and medical diagnostic companies have jointly collaborated, and drafted initial guidelines
to be used for biomarker method development and validation, covering both qualitative
and quantitative assays [Lee et al., 2006]. Conferences such as the Biomarker World
Congress have several meetings annually with attending representatives (domestic and
international) from industry, biotechnology, academia, and government (e.g. FDA).
Biomarker discovery and development success rate to the market place (i.e. clinical
laboratory or point-of-care) is very similar to the pharmaceutical industry, with just a
fraction of the discovered biomarkers being successfully utilized in the clinical laboratory.
Although there has been approximately 4,000 biomarkers reported in the literature, less
than 100 have been cleared for use by the FDA, and less than 10 are routinely used in the
clinics [Biomarker World Congress, 2007]. Of the endogenous biomarkers that are
currently being used, concentration level changes in plasma are all less than 10-fold
increases, with most biomarkers having less than a 5-fold increase in concentration level
[Biomarker World Congress, 2007]. As will be reported in Chapter 4 of this dissertation,
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our proposed candidate biomarker(s) inosine and hypoxanthine from hospital room
emergency room patients exhibiting non-traumatic chest pain; had plasma concentrations
(called total hypoxanthine as inosine is converted to hypoxanthine using purine nucleoside
phosphorylase enzyme) above the 5-fold increase typically found in the currently used
FDA cleared biomarkers.
1.3

Biomarkers of Acute Myocardial Infarction
The biomarkers that are currently used for detection of acute MI are myoglobin,

CK-MB and either cTnI or cTnT. These are biomarkers of cardiac tissue necrosis and can
be used individually, but more emphasis has been placed on using panels of these cardiac
biomarkers together (e.g. simultaneous evaluation of myoglobin, CK-MB and cTnI). The
rationale for using a cardiac panel of biomarkers is that it improves the diagnostic
accuracy, as ultimately more information is gathered to use for patient diagnosis. There
has been other cardiac biomarkers of acute MI over the years, many being replaced as new
discoveries find better biomarkers demonstrating higher specificity and sensitivity (e.g.
lactate dehydrogenase replaced by current acute MI biomarkers).
As can be seen in Table 3 (Cortez Diagnostics, CA, USA) and Figure 1, the cardiac
biomarkers have completely different onset and duration profiles (leading to different halflives). Myoglobin (MW ~17 kDa) is found in muscle tissue and transports cellular oxygen
consumed by muscle mitochondria. Although it is a very sensitive biomarker of muscle
tissue necrosis, it is not totally specific to heart tissue and can also be found in other
muscle tissue (e.g. skeletal). In a medical situation consisting of an ischemic event
involving both cardiac and skeletal muscle, elevated levels of myoglobin may be present
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Table 3. Cardiac tissue necrosis biomarker detection time after AMI onset, normal
individual plasma range, and the biomarker duration time (Information from Cardiac Panel
Test Strip Information Sheet, Cortez Diagnostics, CA, USA).

Marker
Myo

Detection time
after onset of AMI
1-4 hrs

Normal
range
30 - 90 ng/ml

Remain
elevated
< 12 hrs

Test Strip
cut-off
level
70 ng/ml

CK-MB

4-6 hrs

< 5 ng/ml

~24 hrs

5 ng/ml

cTnI

10-12 hrs

ND

60-80 hrs

1 ng/ml
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Figure 1. Serum profile of plasma biomarkers (myoglobin, CK-MB, troponins, and lactate
dehydrogenase (LD)) representing human cardiac tissue necrosis. Profile depicts differing
onset and duration of cardiac biomarkers after an acute MI event. Picture with permission
from Futura Publishing Company, Inc., NY, USA.
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from either form of muscle, thus leading to potential confounding results if only using
myoglobin as the cardiac biomarker.
Instead, many clinical labs utilize multiple cardiac biomarkers (currently called
cardiac panels) to improve patient diagnosis (increases predictive value). CK-MB (MW ~
41 kDa) is an isoenzyme of the creatine kinase (CK) family of enzymes and is primarily
found in heart muscle tissue. Although it is more specific to heart muscle tissue than
myoglobin, it can not be detected until approximately 4-6 hours after the acute MI event.
The latest cardiac biomarkers to be utilized are the cardiac troponins (cTnI, MW 24 kDa
and cTnT, MW 34 kDa). These biomarkers are highly specific to cardiac muscle tissue,
but like CK-MB, are not readily detected until 4-8 hours after the acute MI event. The
high specificity of the troponin proteins can be explained as both are structural components
of the thin filament of cardiac muscle tissue; hence necrosis of the affected cardiac tissue
followed by the body’s elimination of the necrotic tissue into the bloodstream, would cause
a significant elevation of these biomarkers (which neither is normally found at detectable
levels in the bloodstream with the currently used immunoassay techniques).
1.4

Biomarkers of Acute Myocardial Ischemia
There are several plasma biomarkers currently under evaluation for acute

myocardial ischemia; however only one to date has been cleared for use by the FDA. The
current biomarker assays are ischemia modified albumin (IMA), unbound free fatty acids
(FFAu) and choline [Apple et al., 2005]. Of the three, only IMA has received FDA
clearance (2003) for marketing as a diagnostic cardiac biomarker. It is worthwhile to
briefly discuss each of these candidate biomarkers as to their proof of biology (if known)
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and why they appear elevated in the bloodstream under conditions of acute cardiac
ischemia.
Choline (HOCH2CH2N+(CH3)3) is one major product formed from the
phosphodiesteric cleavage of membrane phospholipid phosphatidylcholine. During an
ischemic event, phospholipase D (PLD) is activated and cleaves membrane
phosphatidylcholine into phosphatidic acid and choline, which is subsequently released
into the blood stream and can be detected. Evaluation of choline was made using LC-MS
technology. At the time of the review article describing its potential use as a biomarker, it
was recommended that the development of rapid point-of-care and central laboratory assay
were still needed to further evaluate this biomarker’s usefulness [Apple et al, 2005]. This
recommendation is not surprising as most clinical laboratories utilize commercially bought
kit assays, which are typically immunological techniques (e.g. enzyme linked
immunosorbent assay (ELISA)).
Ischemia modified albumin (IMA) is the term given to serum albumin that has been
modified by the reaction with free radicals generated by heart tissue undergoing acute
cardiac ischemic conditions. The premise of this biomarker candidate is that free radials
(e.g. hydroxyl) generated by ischemic heart tissue can react with albumin in the
bloodstream forming a “modified albumin”, which can be subsequently detected using a
colorimetric technique. The exact mechanism is still unclear, but it is hypothesized that
free radicals attach irreversibly to the amino end terminus of the albumin protein, creating
a modified albumin moiety. Briefly, the assay utilizes an aqueous cobalt chloride solution,
with cobalt typically able to bind to the amino terminus of serum albumin (which normally
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binds and transports transition metals like cobalt). However, under conditions of acute
cardiac ischemia and the formation of the modified albumin moiety, the cobalt can not
bind to the n-terminus of albumin, and the resulting solution will have an intense blue
color (as cobalt will instead bind with the test reagent dithiothreitol); which is measurable
using a spectrophotometer. A spectrometer can be found used in a routine chemistry
analyzer typically found in clinical laboratories.
Several IMA method conditions are important to list: the avoidance of sample
collection using chelators (e.g. EDTA) as it would interfere with the analysis by binding to
divalent cations (e.g. calcium, cobalt, magnesium), and to analyze the sample within 2.5
hrs of the blood draw (unless stored frozen at -20°C). Currently, there are clinical
chemistry platforms for this analysis with on-going investigations on the potential use of
immunoassay techniques. Although this biomarker has been cleared by the FDA for use,
several clinical studies have reported the test to have significant false positive results (e.g.
increased IMA values may be found in patients with cancer, liver disease, brain ischemia,
end-stage renal disease, and infections [Apple et al., 2005; Asian D. et al., 2005; Wu,
2003]) and the analysis cost is fairly high (2006 US Medicaid reimbursement cost was
~$47 per test). As the diagnostic predictive accuracy of using IMA results alone is <50%
[Sinha et al, 2003, Bagavan et al., 2003], it is important to mention that the FDA clearance
of the IMA test was based on its use in conjunction with two other acute MI diagnostic
tests (e.g. electrocardiogram (ECG) and cardiac troponin (e.g. cTnI)), which significantly
increased the overall patient diagnostic accuracy.
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Free fatty acids (FFA) are typically found in serum bound to albumin with a small
amount typically found in the unbound form (FFAu, free). However, under conditions of
cardiac ischemia, the levels of FFAu are found elevated, with the exact understanding of
why (mechanism-of-action) the FFAu is found elevated remaining unclear. The FFAu
analysis consists of the binding the unbound FFA to a protein labeled with a fluorescent
tag, and subsequent measurement using a fluorometer. It was recommended that
additional clinical evaluations were necessary to further evaluate this candidate biomarker
[Apple et al., 2005].
1.5

Past Research on Inosine and Hypoxanthine
Inosine and hypoxanthine are found in human plasma at low basal concentrations

(inosine 0.75-1.49 µM, hypoxanthine 1.47-2.94 µM) normally resulting from purine
metabolism [Feng et al., 2000]. Past research has been performed evaluating inosine and
hypoxanthine in humans to explore their possible roles in response to ischemia and to also
determine what role inosine may have as an immunosuppressant. Several research groups
have published articles evaluating nucleotide breakdown products in blood during
ischemic cardiac events (e.g. pacing induced angina, acute MI) and utilized HPLC test
methods for analysis.
For example, one group studied the role of xanthine oxidase in purine metabolism
in ischemic humans [Kock et al., 2003]. They evaluated components such as
hypoxanthine, xanthine and uric acid, but these authors did not measure inosine and
reported insignificant differences in hypoxanthine concentrations (mean [µM], SD)
between normal male individuals (11.9 µM, 4.1), and patients with MI (16.2 µM, 7.1) and
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other ischemic diseases (e.g. angina pectoris, 11.9 µM, 5.0). Our research in Chapter 4
(Section 4.4) focused on addressing the differences in hypoxanthine results from our
experiments using plasma (lithium heparin) and Kock’s group; which used serum with gel
(SST) for their experiments.
Another group studied normal volunteers and patients with documented ischemic
heart disease; utilized an atrial pacing stress test and reported elevated levels of
hypoxanthine using HPLC, but insignificant levels of adenosine, inosine and xanthine
[Harmsen et al., 1981]. While these authors evaluated cardiac ischemic patients and found
hypoxanthine concentrations to be elevated, they also reported insignificant levels of
inosine (hypoxanthine precursor); which our Chapter 4 research reports significant
concentrations of both hypoxanthine and inosine from our study patients. The differences
in inosine results may be explained by differences in the cardiac patient types. Harmsen’s
group used ischemic heart disease patients and performed the atrial pacing stress test,
which may end after a brief period of time (e.g. 20-30 min). This is somewhat different
than what our cardiac patient samples represent; which were all from a local hospital
emergency department’s group of non-traumatic chest pain patients. These patients, which
may have potential acute cardiac ischemia, had reported non-traumatic chest pain that may
have been occurring for many hours (e.g. 2 to >10 hrs.), thus allowing concentrations of
the ATP catabolic by-products (e.g. inosine, hypoxanthine) to elevate in the blood stream.
Toguzov’s group reported a rise in purine metabolic end products in patients with
angina and MI [Toguzov et al., 1989]. Their overall conclusion was that plasma
concentrations of xanthine and uric acid were better indicators of the severity of cardiac
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ischemia than were inosine and hypoxanthine. Since xanthine and uric acid can both be
elevated by other patient medical conditions (e.g. elevated xanthine with xanthine oxidase
deficiency and elevated levels of uric acid with gout); these two substances may have false
positives associated with their use as potential cardiac biomarkers.
Although other research groups have worked with patients with cardiac disease
(e.g. ischemia, acute MI, angina), there have been no reported studies on nucleotide
catabolic by-products in plasma from patients (hospital emergency department) presenting
with non-traumatic chest pain and potential acute cardiac ischemia, nor have any groups
published a simple, rapid and sensitive test method (goal of <10 min and for clinical
laboratory) for nucleotide catabolic components inosine and hypoxanthine in plasma.
Animal research in the area of cardiac ischemia has also been performed with
publications demonstrating inosine and hypoxanthine cardiac efflux utilizing experiments
with animal models such as the dog and pig [Jennings et al., 1981; Backstrom et al., 2003],
with one group using the mouse model and adenosine metabolism inhibitors to study the
mechanism underlying inosine cardio protection [Peart et al., 2001]. Jennings et al. used
the dog (healthy mongrel) model for their experiments. In brief, these investigators
performed in-vitro (excised heart) and in-vivo experiments, inducing ischemia and then
evaluating the eluted nucleotides and their by-products (e.g. inosine, hypoxanthine). They
concluded that when inducing cardiac ischemia on in-vitro (total ischemia) and in-vivo
(severe ischemia) heart tissue, that elevated levels of inosine and hypoxanthine were
detected (after 15 min for in-vivo, after 60 min for in-vitro). Peart et al. used isolated
mouse hearts to evaluate adenosine metabolism inhibitors during periods of cardiac

46
ischemia. Their conclusion was that adenosine deaminase and kinase inhibition (via
enzyme inhibitors) provided cardioprotection (from reducing the xanthine/xanthine oxidase
reaction and the generation of damaging free radicals). Although their research goal
(enzyme inhibitor evaluations using wild type C57/BL6 and transgenic mice) was
somewhat different than our animal model research goal (cardiac ischemia marker proof of
concept using ICR heterogeneous mice), both groups used isolated mouse hearts for the
experiments. To meet the goal of cardiac ischemia marker proof of concept, the isolated
mouse heart tissue represented less potential confounding results (e.g. clean matrix from
Krebs perfusate and removal of body compensations to ischemia) plus the mouse is easy to
use and relatively inexpensive to purchase/maintain.
Backstrom et al. used the pig model for their experiments, with microdialysis
catheterization at several different blood vessel sites (e.g. great cardiac vein, pulmonary
artery), and then used arterial occlusion to induce cardiac ischemia for various times (0, 10,
15 and 60 min). They reported significant dialysate concentrations of inosine and
hypoxanthine at ischemic time points of 15 and 60 min relative to baseline concentrations
(ischemic time point 0 min), and concluded that there was a graded outflow of amino acids
and purines in response to ischemic conditions.
1.6

Research Hypothesis and Significance
The research hypothesis is that during periods of acute cardiac ischemia in patients

presenting with non-traumatic chest pain (hospital emergency department), plasma
concentrations of inosine (hypoxanthine precursor) and hypoxanthine would be
significantly elevated above their normally low endogenous plasma concentrations, and
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potentially becoming candidate biomarkers indicative of the pre-necrotic acute cardiac
ischemic event. As acute cardiac ischemia is an event prior to potential acute myocardial
infarction, the affected heart tissue in the ischemic area is still functional and not yet
necrotic, as are tissue from an acute myocardial infarction (AMI).
The current biomarkers indicative of AMI are relatively large protein components
(e.g. myoglobin, CK-MB, and troponins with each larger than 10,000 Da) which are
released from necrotic heart tissue. However, inosine and hypoxanthine; which are ATP
catabolic by-products and small polar substances (MW inosine 268 Da, MW hypoxanthine
136 Da), are transported by passive diffusion from affected heart tissue into the
bloodstream. Since an acute cardiac ischemic event occurs prior to potential AMI, it is
hypothesized that the concentrations of inosine and hypoxanthine should appear elevated
in the bloodstream prior to elevated concentrations of protein biomarkers indicative of
AMI (which are detected several hours after the AMI event).
The significance of this research would be the identification of potential candidate
biomarker(s) of acute cardiac ischemia and the development of a rapid analysis (<10 min)
to use for the biomarker measurement. Ideally, EMS personnel would benefit from this
biomarker and rapid test method to guide in their diagnostic and treatment steps for nontraumatic chest pain patients, as there are more than ten medical conditions other than
acute MI that may cause non-traumatic chest pain (e.g. anxiety attack, acid reflux, angina).
However, one limitation of using elevated concentrations of inosine and hypoxanthine as a
biomarker of acute cardiac ischemia is these biomarkers may not differentiate a patient
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experiencing acute cardiac ischemia prior to AMI, or experiencing cardiac angina without
AMI.
1.7

Overall Research Experimental Design
The research is divided into three study phases, with each study phase being

completed prior to beginning the next (i.e. each subsequent study phase builds from the
prior study phase). The study phases are briefly described below with a general outline of
all three phases listed afterwards.
Phase I (Chapter 2) study has the overall goal of comparing control and ischemic
isolated mouse hearts to identify potential biomarkers of acute cardiac ischemia. HPLC
methodologies (DAD and MS detection) will be developed and used for all sample
analysis from Phase I experiments. As aspirin (ASA) is currently used for human patients
suspected of undergoing acute myocardial infarction (a condition that may occur after an
acute cardiac ischemic event), it will be investigated (Chapter 3). Since aspirin is rapidly
metabolized to salicylic acid (SA) in the body; SA will be investigated and used for the
additional isolated mouse heart experiments undergoing ischemic conditions. The goal is
to determine the effect of SA on the biomarkers from Chapter 2 experiments.
Phase II (Chapter 4) study has the goal of evaluating blood samples to determine if
the biomarker identified in Chapter 2 is present in human plasma and then measure the
concentrations. HPLC methodology (UV detection) will be used for all sample analysis in
Phase II studies. IRB approval will be obtained for the use of blood samples represented
healthy normal individuals and non-traumatic chest pain patients (from a local hospital
emergency department). Additional experiments will be performed using different types of
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sample collection additives (e.g. serum separator tube (SST), matched sets of heparin
plasma and SST). The goal is to determine if the SST additive (e.g. gel) causes potential
artifacts in biomarker concentration and state the preferred blood sample collection
additive for any future work on the potential biomarkers.
Phase III (Chapter 5) study has the overall goal of developing a rapid and simple
screening assay (i.e. potential diagnostic tool) to use in a clinical environment. A
microplate luminometer will be purchased, setup and utilized for plasma (lithium heparin)
analysis. Evaluations of enzyme (e.g. xanthine oxidase, purine nucleoside phosphorylase)
concentration and incubation times will be performed to optimize assay conditions and
achieve a rapid analysis time. The screening assay will be tested on plasma from healthy
normal individuals and cardiac patients with acute myocardial infarction (as defined by
elevated levels of cardiac troponin I). The goal is to determine if potential biomarker
concentrations are significantly different between these two groups (normal subjects versus
acute MI patients).
Each of the three phases of studies can also be listed as follows:
Phase I - Animal studies to identify potential biomarkers of acute cardiac ischemia
and demonstrate biomarker proof-of-concept
•

Evaluate potential biomarker(s) from animal model (isolated mouse hearts)

undergoing 20 min acute global cardiac ischemic conditions. Evaluate test (ischemic) and
control animal perfusate samples (n=6 each group) using HPLC methodology.
•

Evaluate effects of salicylic acid (aspirin metabolite) in Krebs buffer solution on

the potential biomarker(s) levels, as aspirin (platelet inhibitor) is currently used for initial
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treatment on patients presenting with non-traumatic chest pain and potential acute
myocardial infarction.
•

Develop quantitative HPLC-DAD (diode array detection) test method for

evaluation of Krebs perfusate samples from the animal experiments. Utilize LC-MS
method for biomarker component identification.
•

Calculate total biomarker efflux (area under the curve, AUC) and utilize statistics

(e.g. t-test, ANOVA) for data analysis on control and test group results.
Phase II - Human plasma evaluation for identified biomarker(s) from Phase I studies
•

Obtain human plasma samples (n=20 each group) from emergency department

(ED) non-traumatic chest pain patients and healthy individuals (controls, non-symptomatic
for acute cardiac ischemia) following institutional review board (IRB) and hospital
departmental approvals.
•

Develop and validate HPLC-UV method for quantitative evaluation of inosine and

hypoxanthine in human plasma.
•

Statistically evaluate HPLC plasma results using parametric techniques (e.g. t-test)

using α=0.05 with p<0.05 demonstrating statistical significance between test and control
group plasma samples.
•

Evaluate effects of sample collection matrix (e.g. lithium heparin plasma, serum

separator tube) on levels of inosine and hypoxanthine from human samples.
Phase III – Develop rapid test method for biomarker(s) from Phase II studies
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•

Develop a rapid, simple, and sensitive plasma luminescence test method (<10 min

analysis time) for potential use by emergency medical services (EMS) or clinical lab
environment.
•

Evaluate plasma samples (n=6 each) from healthy individuals and hospital acute

MI patients (hospital documented elevated cTnT levels). Compare results statistically
using t-test and using a calculated biomarker cut-off limit (e.g. 99th percentile).
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CHAPTER 2. Animal Studies to Demonstrate Proof-of-Concept, “HPLC
Determination of Inosine, a Potential Biomarker for Initial Cardiac
Ischemia using Isolated Mouse Hearts”

2.1

Introduction
In this chapter of research, animal studies were performed to identify potential

biomarker(s) of acute cardiac ischemia and to demonstrate the potential biomarker(s)
proof-of-concept (via mechanism of action). The rationale of using isolated mouse hearts
for these experiments was to eliminate potential confounding factors (e.g. body
metabolism, body compensatory mechanisms) that may occur with in-vivo type
experiments. Ischemia is defined as a reduced blood flow and results in reduced oxygen
supply to the affected site (tissue). As a consequence to the lack of oxygen in heart muscle
tissue, adenosine triphosphate (ATP) production in the cardiac cell’s mitochondria would
be limited to anaerobic production.
Thus, it is important to understand how the heart utilizes ATP, a high energy
phosphate molecule, to perform its circulatory function. The heart is highly energydependent on ATP, which is made in cardiac cellular mitochondria by either aerobic
(oxidative phosphorylation via electron transport chain) or anaerobic (glycolysis)
processes. The aerobic process is heavily oxygen dependent and generates approximately
80% of cardiac cellular ATP. The anaerobic process is independent of oxygen and
produces approximately 20% of the cardiac cellular ATP; with lactic acid as a by-product.
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For production of large quantities of ATP, human cardiac cells have an abundance
of mitochondria which comprise approximately 40-50% of the cardiac cellular mass.
When cardiac tissue is subjected to periods of constant oxidative stress (e.g. cardiac
ischemia), insufficient oxygen is available for cardiac mitochondria to aerobically
synthesize the ATP required for normal cardiac function. This causes a cellular
accumulation of ATP metabolic by-products (e.g. adenosine diphosphate (ADP),
adenosine monophosphate (AMP)) and activates normally dormant enzymes (e.g. 5´nucleotidase, adenosine deaminase, purine nucleoside phosphorylase and xanthine oxidase)
to catabolize the ATP by-products to substances such as adenosine, inosine, hypoxanthine,
xanthine and uric acid for cardiac cellular elimination [Abd-Elfattah et al., 2001]. In
human cardiac tissue, another source of ATP metabolic by-products is through metabolism
of diadenosine polyphosphates, which are released from cardiac-specific secretory granules
during periods of cardiac metabolic or ischemic stress to provide cellular protective
functions [Luo et al., 2004].
Inosine (9-β-D-ribofuranosylhypoxanthine) is an endogenous purine nucleoside
normally found in the human body as a degradation component of purine metabolism. In
human plasma, inosine is metabolized in red blood cells with a reported half-life of <5 min
with endogenous plasma levels found in trace amounts (e.g. low ng/mL) [Viegas et.al.,
2000]. In humans, nature has provided a cellular biochemical mechanism to help conserve
energy in producing the required large quantities of ATP for cardiac cellular use (called
salvage pathway), which can convert cellular inosine back to ATP via several enzymatic
steps; thus recycling cellular inosine [Nelson et al., 2000]. However, in periods of constant
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cardiac oxidative stress (e.g. 20 min), cardiac cells buildup significant amounts of ATP
metabolic by-products, which activate normally dormant enzymes to catabolize ATP byproducts, which then become systemically available prior to their elimination.
The research hypothesis is that prior to extra-cellular biomarkers (e.g. free radical
modified serum albumin) appearing in the bloodstream from cardiac ischemic events,
plasma inosine levels should be elevated above normally low endogenous levels, thus
becoming a useful biomarker of pre-necrotic acute cardiac ischemia. Adenosine, another
nucleoside metabolic by-product of ATP catabolism is metabolized by red blood cells and
has a very short plasma half-life (e.g. ~15 sec); thus making it more difficult to
quantitatively measure in plasma [Mei et.al., 1996]. The three other metabolic by-products
(xanthine, hypoxanthine and uric acid) are normally found at higher levels in the plasma,
but would lack the necessary specificity due to potential contributions from other human
disease state conditions (e.g. plasma uric acid levels elevated in gout; plasma xanthine
levels elevated in xanthine oxidase deficient individuals).
The ICR (Institute of Cancer Research) outbred mouse [Dohm, 2004] was used as
the animal model for all isolated heart experiments and utilized a Langendorff apparatus
[Xi et al., 1998]. For sample analysis, a developed analytical method utilized a high
performance liquid chromatographic diode array detection (HPLC-DAD) for the detection
and quantification of inosine in Krebs-Henseleit (Krebs) buffer solution. A Synergy C18
column (hydrophobic/hydrophilic reversed phased retention) at a flow rate of 0.6 ml/min
with an aqueous mobile phase of trifluoroacetic acid (0.05% TFA in deionized water pH
2.2, v/v) and methanol gradient was used for component separation. The assay detection
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limit for inosine in Krebs buffer solution was 500 ng/mL using a 100 μL neat injection.
The HPLC results were used to determine total cardiac effluxed inosine (AUC) into the
Krebs effluent for each mouse during acute global cardiac ischemia (oxidative stress) and
compared to percent cardiac ventricular functional recovery to determine if a relationship
exists amongst this cardiovascular parameter during periods of acute global cardiac
ischemia.
2.2

Experimental

2.2.1

Chemicals, Mobile Phase and Krebs Buffer Solution
Hypoxanthine and xanthine were purchased from Acros Organics (Fair Lawn, NJ,

USA). 2,3-dihydroxybenzoic acid (DHBA), 2,5-dihydroxybenzoic acid, salicylic acid
(SA), adensosine, inosine and uric acid were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Sodium chloride, sodium bicarbonate, potassium chloride, magnesium sulfate,
monobasic potassium dihydrogen phosphate, dextrose and calcium chloride were used to
prepare the Krebs buffer solution and all were purchased from Sigma-Aldrich. All
purchased chemicals were ACS reagent grade or better. The Krebs buffer solution [118.5
mM NaCl, 25.0 mM NaHCO3, 11.1 mM C6H6O6, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM
MgSO4 and 2.5 mM CaCl2] was prepared in ultrapure deionized water with pH 7.4 and
95%O2:5%CO2. For mobile phase preparation, trifluoroacetic acid (TFA) was reagent
grade and methanol was Optima HPLC grade and both were purchased from Fisher
Scientific (Fair Lawn, NJ, USA). Ultrapure distilled and deionized water (18 MΩ-cm)
used for HPLC work was prepared in-house using Purelab Ultra deionized water system
(US Filter, Lowell, MA, USA) and filtered prior to use.
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2.2.2

Preparation of Standard Solutions
Stock standards of 93.6 µM adenosine, 93.2 µM inosine, 183.7 µM hypoxanthine,

164.4 µM xanthine and 148.7 µM uric acid were prepared in deionized water and stored at
4°C. Working standards (1:10 dilution of stock standard) of each component were
prepared in Krebs buffer solution and maintained at -20°C along with the mouse Krebs
buffer eluant samples. The working standards stored at -20°C were stable for at least 6
months.
2.2.3 HPLC-UV and HPLC-MS Equipment Set Points
For inosine quantification and diode array spectral purity, the HPLC equipment
consisted of Agilent Model 1100 Quaternary HPLC-DAD and Chemstation software (Palo
Alto, CA, USA). The DAD was set to acquire complete UV spectrum for component
specificity with 240 nm used for quantification of inosine and the other ATP metabolic byproducts. For inosine confirmation, LC/MS was used and the equipment consisted of a
Shimadzu LCMS-2010A HPLC coupled to a single quadrapole mass spectrometer using
LCMS Solutions software (Columbia, MD, USA). The HPLC-MS conditions consisted of
using ESI with the following instrument set points (heating block at 300°C, nebulizer at 4
L/min nitrogen, interface voltage at 2 kV) and full scan acquisition using positive ion
mode.
The analytical column for both HPLC-DAD and HPLC-MS analysis was a
Synergi™ Hydro-RP C18, 150 mm x 3 mm I.D., 4 μm packing, 80 Å (Phenomenex®,
Torrance, CA, USA). The C18 guard column was a 30 mm x 4.6 mm I.D., 40-50 μm
pellicular packing (Alltech, Deerfield, IL, USA). The mobile phase consisted of aqueous
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trifluoroacetic acid (0.05% TFA in deionized water, v/v, and pH 2.2) and methanol
gradient. The mobile phase gradient was linear with time course as follows (95:5 0.05%
TFA in deionized water: methanol, v/v at 0 min; 70:30 0.05% TFA in deionized water:
methanol, v/v at 12 min; 10:90 0.05% TFA in deionized water: methanol, v/v at 13 min
and held 3 min, and 95:5 0.05% TFA in deionized water: methanol, v/v at 17 min).
The mobile phase was degassed automatically using an Agilent 1100 membrane
degasser with a flow-rate of 0.6 ml/min. An injection volume of 100 μl of the Krebs buffer
eluant was made using an autosampler. Typical HPLC operating pressure was
approximately 150 bar with ambient column oven temperature and 345 kPa back-pressure
regulator (SSI, State College, PA, USA) to prevent mobile phase outgassing in the
detector.
2.2.4

ICR Mouse Experiment Conditions
ICR mice were used for all isolated mouse heart experiments with morphometric

characteristics and baseline cardiac function of the adult mice (ICR strain) provided in
Table 4. The mice were anaesthetized; hearts surgically removed and isolated using the
Langendorff apparatus (Figure 2). Global cardiac oxidative stress was accomplished by
adjusting the Krebs buffered solution to zero flow through the heart for 20 min. Upon
heart reperfusion, approximately 1.5 mL samples of Krebs buffered eluant from the
isolated mouse hearts were collected at predetermined time-points (0, 1, 3, 5, 10 and 20
min) in plastic bullet centrifuge tubes and frozen at -20°C until HPLC-DAD analysis.
To evaluate the effects of oxidative stress on the mouse heart, established
cardiovascular measurements (e.g. ventricular functional recovery) were performed on
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Table 4. Morphometric characteristics and baseline cardiac function of the adult mice (ICR
strain).
________________________________________________________________________
Control
Ischemia-Reperfusion Test
(n = 6)
(n = 6)
________________________________________________________________________
Body Weight (g)
42.2 ± 1.3
38.7 ± 2.1
Heart Wet Weight (mg)
258 ± 6
242 ± 14
Heart Rate (bpm)
368 ± 23
345 ± 23
Developed Force (g)
0.81 ± 0.19
1.12 ± 0.12
Rate-Force Product (g x bpm)
308 ± 80
372 ± 49
Coronary Flow (ml/min)
2.3 ± 0.2
1.7 ± 0.1
________________________________________________________________________
Values are mean ± SEM. No significant difference (P>0.05) between the groups was
found for the listed parameters, except coronary flow.

59

Experiments Using
Modified Langendorff Apparatus
Krebs buffer
(constant temp)

Air temperature
measurement

Heart tensioner
device

Syringe pump
for admin drugs

Suspended
mouse heart,
viable for
several hours.

Courtesy of Dr. Lei Xi, VCU Cardiology

Figure 2. Modified Landendorff apparatus used for all animal (mouse) experiments. The
suspended isolated heart has Krebs buffer solution perfusing through it to provide
sufficient nutrients (e.g. buffer salts, glucose, oxygen etc.) for experiments.
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both control (non-ischemic conditions) and test (ischemic conditions) animals (n=6 for
each group). Our methodology for evaluating the isolated perfused mouse heart has been
previously described [Xi et al., 1998]. In brief, animals are anesthetized with an
intraperitoneal injection of pentobarbital sodium ([100 mg/kg] with 33 IU heparin added).
The heart was removed and immediately placed in ice-cold Krebs buffer. The aorta was
cannulated within 3 min onto the Langendorff perfusion system and the heart was perfused
in a retrograde fashion at a constant pressure of 55 mmHg with Krebs buffer gassed with
95%O2 and 5%CO2. The pH of the buffer and the heart temperature were maintained at
7.35-7.50 and 37±0.5ºC, respectively. A force-displacement transducer (Grass, FT03) was
attached to the apex via a metal hook/surgical thread/pulley system to continuously record
and measure ventricular contractile force and heart rate. For each heart the resting tension
was set at ~0.3 g in the beginning of the experiment.
The protocol for the test group consisted of 30 min of stabilization, 20 min of zeroflow global ischemia, and 30 min of reperfusion [Xi et al., 1998]. Time-matched normoxic
perfusion was carried out for the control group. At the end of each experiment, the heart
was removed from the Langendorff system, quickly weighed and stored at -20°C.
2.2.5

Sample Preparation, Stability, and Instrument Precision Evaluation
Prior to HPLC analysis, perfusate samples frozen at -20°C were thawed to ambient

temperature, mixed thoroughly by inversion and transferred to plastic autosampler vials for
subsequent direct injection into the HPLC-DAD system. To evaluate sample stability in
the perfusate solution and instrument precision; prepared samples in autosampler vials
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were stored at ambient lab temperature overnight and re-injected (n=3 times) into the
HPLC for analysis.
2.2.6

Component Retention Times, Inosine Calibration and AUC Calculations
During HPLC method development and validation, standards of adenosine (3.7 to

93.6 µM), inosine (3.7 to 93.2 µM), hypoxanthine (7.3 to 183.7 µM), xanthine (6.6 to
164.4 µM) and uric acid (5.9 to 148.7 µM) were prepared in Krebs buffer solution.
Standard curve linearity (non-weighted) of all components was acceptable with all
correlation coefficients >0.995. During subsequent analytical runs, a single point
calibration standard mixture (9.3 µM inosine, 18.4 µM hypoxanthine, 9.4 µM adenosine,
16.4 µM xanthine and 14.9 µM uric acid) was prepared in Krebs buffer solution and was
used for identifying component retention times and quantification of inosine found in test
samples. Using UV detection at 240 nm, component peak area and external
standardization were used for inosine computations. For determining inosine AUC on test
samples, the trapezoidal rule computation using Excel software was performed on inosine
sample values from 0 to 20 min.
2.3

Results and Discussion

2.3.1

Additional Evaluation for Hydroxyl (·OH) Free Radicals
During periods of cardiac oxidative stress (e.g. acute myocardial infarction), the

heart is deprived of the oxygen needed for ATP synthesis. In the absence of oxygen
dormant enzymes activate whereby ATP is sequentially converted to ADP, AMP,
adenosine, inosine and hypoxanthine. Upon reperfusion of the heart with oxygenated
blood or oxygenated Krebs solution, additional cellular enzymatic conversions transpire
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with xanthine oxidase converting hypoxanthine to xanthine and uric acid. A metabolic byproduct of xanthine oxidase is the formation of hydrogen peroxide (H2O2) which is
normally converted by glutathione peroxidase to H2O. However, in the presence of Fe2+,
H2O2 may be converted to a hydroxyl free radical (·OH) via the Fenton and Haber-Weiss
reactions (Figure 3) [IUPAC, 1997].
The (·OH) is a known potent reactive oxygen species (ROS) and can cause damage
to cellular components (e.g. lipids, proteins, nucleic acids) [Tardif and Bourassa 2000]. To
investigate the formation of ROS, one research objective was to evaluate and estimate the
amount of (·OH) generated from 20 min of global cardiac ischemia using isolated mouse
hearts. In several of the initial experiments, SA [1 mM] was fortified in the Krebs buffer
solution (pH adjusted 7.4) to react with (·OH) and form the reaction products of 2,3 and
2,5-DHBA isomers [Onodera et al., 1991; Coudray et al., 2000].
The HPLC-DAD conditions that were used for inosine determination resolved
prepared standards [13 ng/mL or 86 nM] of the 2,3 and 2,5-DHBA isomers from other
Krebs eluant sample components (e.g. SA, adenosine, inosine, hypoxanthine etc.).
However, in our experiments performed using SA, we did not observe either the 2,3 or 2,5DHBA isomers in the sample chromatograms from mouse hearts that were subjected to
global cardiac ischemia. It is possible that the initial level of SA [1 mM] added to the
Krebs buffer solution increased the total solute concentration to a level, which reduced the
solubility of 2,3 and 2,5-DHBA isomers and therefore made each analytically undetectable.
Lower concentrations of SA [e.g. ≤ 1 µM] may in theory resolve this aspect of ROS
generation from mouse acute global cardiac ischemia.
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Figure 3. Schematic drawing of cardiac cellular ATP catabolism due to oxidative stress
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2.3.2

HPLC-DAD and HPLC-MS Identification
The HPLC-DAD method was used for determining all of the following components

(adenosine, inosine, hypoxanthine, xanthine, uric acid, 2,3-DHBA and 2,5-DHBA
isomers). The mobile phase aqueous component 0.05% TFA in deionized water was
chosen as pH ~2.3 provided good peak shapes on all components and a low pH was
necessary to reduce peak tailing on the acidic components (e.g. 2,5-DHBA has pKa ≈ 2.9).
The Synergi™ Hydro-RP C18 (polar endcapped) and Synergi™ Polar-RP C18 (ether-linked
phenyl) columns of identical dimensions were evaluated for use. While both columns
worked well for inosine and polar components (e.g. adenosine), the Synergi™ Hydro-RP
C18 was selected for overall analysis as it provided good component peak shape and
sufficient resolution of all components.
Other components evaluated using this method have HPLC retention times as
follows (uric acid 2.8 min, hypoxanthine 3.9 min, xanthine 4.2 min, adenosine 5.7 min,
CK-MB 8.2 min, 2,3-DHBA 8.4 min, 2,5-DHBA 10.2 min, myoglobin 14.1 min, atrial
natriuretic peptide 14.5 min, brain natriuretic peptide 15.0 min and salicylic acid 15.4
min). Both cardiac troponin I and troponin T were not detected using this HPLC method.
An HPLC-DAD chromatograms overlay from a mouse subjected to 20 min acute global
cardiac ischemia and a control mouse (non-ischemia) are presented in Figure 4 with
inosine elution at 5.9 min.
To evaluate perfusate sample stability, the prepared samples were initially injected
and analyzed by HPLC-DAD. The samples were subsequently stored overnight on the
autosampler at ambient lab temperature and re-injected (n=3 times) to evaluate both for
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Figure 4. HPLC-DAD chromatograms overlay of control (025-2501.D) and 20 min global
cardiac ischemia (026-2601.D) mouse perfusate samples. Inosine (RT 5.9 min) and
HPLC-ESI/MS mass spectrum identifying inosine (MW 268 Da) as a potential early
biomarker of global cardiac ischemia is demonstrated in the ischemic mouse heart
perfusate. The chromatogram overlay between control and 20 min global cardiac ischemia
also demonstrates consistent gradient repeatability.

min
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changes in component levels due to possible synthesis or degradation reactions from
potential enzymes eluted in the perfusate and to evaluate instrument precision. In all reinjected perfusate samples, component levels remained constant (≤ 4% RSD) indicating
stability overnight at ambient temperature and the absence of appreciable levels of
nucleoside and purine converting enzymes in the perfusate.
2.3.3

HPLC-MS Identification of Inosine as Potential Initial Ischemia Biomarker
An HPLC-MS was used to identify inosine at retention time 5.9 min in samples

from test mice subjected to oxidative stress. The HPLC analytical column, mobile phase
gradient and flow rate were identical to that used in the HPLC-DAD method. The mass
spectrum for inosine (MW 268 Da) is presented in Figure 4. It was acquired using the MS
positive ion mode, which provided a good mass spectral quality match against a prepared
standard of inosine in Krebs buffer solution. The full scan spectrum was achieved using
up-front collision induced dissociation (CID) and nitrogen as the collision gas. The mass
spectrum base peak (137 Da) represents the cleavage of the ribose entity from inosine
leaving a protonated hypoxanthine (MW 136 Da) (Figure 5).
2.3.4 Evaluation of Inosine AUC and Other Cardiovascular Parameters
Initially, the focus was on identifying cardiac protein or peptide biomarkers (e.g.
ANP, BNP) that may be released from ischemic myocardium; however in comparison with
non-ischemic mouse hearts only inosine (22 to 69 fold) and xanthine-like products (e.g.
hypoxanthine (>7 fold), xanthine (~3 fold), uric acid (~3 fold)) were found at higher levels
in globally ischemic mouse hearts. Figure 6 is a profile of mouse hearts subjected to
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HPLC ESI/MS - Positive Ion Mode

Inosine – 268 Daltons

Inosine (M+1) – 269 Daltons

Hypoxanthine (M+1) – 137 Daltons

Figure 5. HPLC-ESI/MS positive ionization mode of inosine (MW 268 Da) with
fragmentation to hypoxanthine (MW 136 Da).
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Mean ATP Catabolic By-Products
under Oxidative Stress
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Figure 6. Profile of the mean (±SD) ATP catabolic by-products detected in Krebs solution
versus reperfusion time after 20 min mouse global cardiac ischemia (n=6 mice). Control
mice (n=6, non-ischemia) are not plotted with undetectable levels of ATP catabolic byproducts in all sample time points (0, 1, 3, 5, 10 and 20 min).
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oxidative stress with individual ATP degradation by-product components (mean ± SD)
plotted against Krebs buffer reperfusion time. As can be seen in Figure 6, inosine was the
component which had the highest response with detectable component amounts found at
low µM levels, after 20 min global cardiac ischemia (n=6 mice). The control mice (n=6,
non-ischemia) are not shown, as there were undetectable levels of all ATP catabolic byproducts in each sample time point (0, 1, 3, 5, 10 and 20 min).
Cardiovascular parameter (e.g. percent cardiac ventricular functional recovery) was
measured and reported with the calculated inosine AUC results (Table 5). As can be seen
from Table 5, inosine efflux was present in test mouse heart perfusate samples which were
subjected to oxidative stress and was not detected in control mouse heart perfusate
samples. However, for both controls and test mice, the percent cardiac functional recovery
ranged from 39 to 92% with the lowest measured cardiac functional recovery being in test
mouse hearts which had the largest amount of inosine present in the Krebs buffer solution
(e.g. test mouse with 2, 469 ng min ml-1 AUC inosine effluxed with 39% cardiac
functional recovery). This may indicate that mouse hearts which are injured to a greater
degree from the effects of oxidative stress efflux more inosine from ATP by- product
degradation. Further studies with larger test and control mouse sample size (e.g. n=10)
would be necessary to statistically interpret this observation.
2.4

Conclusion
The preliminary results suggest that the concentration of inosine found in test

animals subjected to cardiac oxidative stress may serve as a potential biomarker indicative
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Table 5. Inosine washout and cardiac ventricular functional recovery in Langendorff
mouse hearts following aerobic perfusion and 20 min global ischemia.

Sample
Type

Inosine AUC 0-20 min
[ng min / mL]

% Cardiac
Functional
Recovery

Control
Control
Control
Control
Control
Control
Test
Test
Test
Test
Test
Test

N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
653
962
954
1,003
2,469
2,583

70
72
74
82
81
64
92
84
77
53
39
52
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of early cardiac ischemia. This can be explained by ischemic myocytes undergoing
nucleotide purine catabolism in the absence of oxygen with subsequent activation of
dormant cellular enzymes and generation of degradative breakdown products of ATP.
Preliminary human studies will need to be undertaken to determine the validity of this
hypothesis.
Additional research from our group will be performed on plasma samples obtained
from hospital admitted patients suspected of undergoing acute myocardial infarction to
determine if plasma levels of endogenous inosine are significantly elevated during periods
of cardiac oxidative stress. If inosine plasma levels are found to be significantly elevated
in samples obtained from patients undergoing acute myocardial infarction, inosine should
be recommended as a potential biomarker for the initial cardiac ischemic event, and may
be useful in indicating the need for immediate medical treatment, potentially improving
patient outcome.
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CHAPTER 3. Animal Studies to Evaluate Salicylic Acid, “Effects of
Salicylic Acid on Post-Ischemic Ventricular Function and Purine Efflux
in Isolated Mouse Hearts”

3.1

Introduction
Aspirin (acetyl salicylic acid, ASA) is one of the most widely used drugs in the

world and has been used for many years for its analgesic, anti-pyretic, anti-inflammatory
and anti-platelet (blood thinning) properties (Vane et al., 2003; Schror, 1997; Evans et al.,
1968). ASA (160 or 325 mg dose) is routinely administered with other cardiac
medications as part of initial emergency treatments to patients presenting with chest pain
and potential acute myocardial infarction (MI) to inhibit platelet aggregation at the site of
cardiac thrombosis (Feldman et al., 1999; Antman et al., 2004; Abarbanell et al., 2001;
Kosowsky, 2006). A 325 mg dose of aspirin can have plasma concentration maximums
(Cmax) of 67 µM acetyl salicylic acid and 188 µM salicylic acid (Merck 11th Edition,
1989). Aspirin is also used chronically by many individuals for other medical conditions,
with plasma salicylic acid concentrations ranging from 145 to 725 µM (analgesia) and
1,086 to 2,172 µM (anti-inflammatory) (Moffat et al. 1986).
Aspirin’s mechanism of action is well documented with interactions causing
irreversible inhibition of both cyclooxygenase isoenzymes (COX-1, COX-2) (Smith et al.,
1971; Schror, 1997). The mechanism for ASA inhibiting platelet aggregation is through
irreversible acetylation of the COX-1 enzyme which blocks synthesis of thromboxane A2,
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a platelet aggregator and vasoconstrictor (Vane et al., 2003). Other reported medical uses
of ASA require higher blood concentrations (e.g. a rheumatoid arthritis patient may require
1.5 to 2.5 mM ASA and an anti-inflammatory dose may require sodium salicylate levels of
0.5 to 5 mM) (Nulton-Persson et al., 2004; Smith et al., 1971). In humans, ASA is rapidly
metabolized (half-life ~3-4 hrs) and excreted via phase I metabolism (60% via
deacetylation to salicylic acid (SA)) and phase II metabolism (~ 40% via conjugated
products) (Rowland et al., 1968).
In addition a recent publication reported inhibitory effects of both ASA and SA on
rat cardiac mitochondrial respiration (Nulton-Persson et al., 2004). These authors found
that ASA and SA both could reduce NADH supply to the electron transport chain in
isolated rat cardiac mitochondria, thus reducing ATP synthesis (via inhibition of oxidative
phosphorylation). They also demonstrated a negative dose-response effect from both ASA
and SA (0-10 mM concentration range) on cardiac mitochondrial respiration under nonischemic conditions. Other research was performed demonstrating the inhibitory effects of
ASA and SA on xanthine oxidase, which would inhibit enzymatic conversion of
hypoxanthine to xanthine and uric acid (Carlin et al., 1985; Masuoka and Kubo, 2003).
To this context, the present study was designed to further examine the effects of SA
(0, 0.1 and 1.0 mM) on ATP catabolic by-products (e.g. inosine and hypoxanthine) along
with an indirect evaluation of purine nucleoside phosphorylase (PNP) enzyme activity
(indicated by inosine/hypoxanthine conversion ratio). We hypothesized that higher
concentrations of SA (e.g. 1.0 mM) coupled with periods of acute cardiac ischemia may
potentiate the ischemic adverse effects on heart tissue via increased uncoupling of
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oxidative phosphorylation and subsequently enhanced efflux of ATP catabolic by-products
such as inosine, which has been proposed in our recent publication (Farthing et al., 2006)
as a potential biomarker of acute cardiac ischemia. The morphometric characteristics and
baseline cardiac function data from controls (non-ischemic and without SA) and test
(ischemic and without SA) animals from Chapter 2 research were used for statistical
comparisons to the experimental groups exposed to SA in this chapter of research.
3.2

Experimental

3.2.1

Chemicals, Standards and Krebs Buffer Solution
All experimental chemicals were purchased and solutions prepared as per our

recent published work (Farthing et al., 2006). Briefly, ACS grade or better purity
hypoxanthine, xanthine, trifluoroacetic acid (TFA) and methanol (Optima) were purchased
from Acros Organics (Fair Lawn, NJ, USA). Salicylic acid, adenosine, inosine, uric acid,
sodium chloride, sodium bicarbonate, potassium chloride, magnesium sulfate, monobasic
potassium dihydrogen phosphate, dextrose, ethylenediaminetetraacidic acid (EDTA) and
calcium chloride were all purchased from Sigma-Aldrich (St. Louis, MO, USA).
Stock and working standards of adenosine (374.2 µM), inosine (372.8 µM),
hypoxanthine (734.7 µM), xanthine (657.4 µM) and uric acid (594.8 µM) were prepared in
deionized water and stored at 4°C as per work (Farthing et al., 2007). The working
standards were maintained at -20°C along with the mouse Krebs buffer perfusate samples
and demonstrated stability for at least 6 months. The Krebs buffer solution consisted of
either 0, 0.1 or 1.0 mM SA and 118.5 mM NaCl, 25.0 mM NaHCO3, 11.1 mM C6H6O6, 4.7
mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 0.5 mM EDTA and 2.5 mM CaCl2 using in-
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house prepared deionized water (final pH 7.4 and continuously gassed with
95%O2:5%CO2 during the isolated heart experiments). For HPLC analysis, deionized
water (18 MΏ-cm) used was produced and filtered using US Filter Purelab Ultra deionized
water system (Lowell, MA, USA).
3.2.2

Langendorff Isolated Mouse Heart Preparation and Experimental Protocols
All animal experimental conditions were similar to our published work (Farthing et

al., 2006; Xi et al., 1998). Adult male mice (ICR strain) were used for all cardiac ischemia
experiments with morphometric characteristics, baseline cardiac function, and ANOVA
results presented in Table 6. The protocol for Groups II, III, and IV consisted of 30 min of
stabilization, 20 min of zero-flow global ischemia and 30 min of reperfusion (Figure 7).
Time-matched normoxic perfusion (for 80 min) was carried out for the Control group and
Group I. Briefly, the mice were anaesthetized; hearts quickly isolated and cannulated onto
a Langendorff apparatus within 3 min. Following the 30 min of stabilization period, global
ischemia was accomplished by stopping heart perfusion inflow for 20 min. Upon heart
reperfusion, approximately 1.5 mL samples of Krebs buffered perfusate from the isolated
mouse hearts were collected at predetermined time-points (0, 1, 3, 5, 10 and 20 min) into
plastic bullet centrifuge tubes and immediately frozen at -20°C. At the end of each
experiment, the heart was removed from the Langendorff system and quickly weighed.
The present study measured simultaneously both cardiovascular parameters (e.g.
coronary flow rate, heart rate and cardiac developed force) and efflux of ATP catabolic byproducts (e.g. inosine and hypoxanthine evaluated in Krebs perfusate samples) for each of
the experimental groups. The control group consisted of six aerobically perfused hearts
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Table 6. Morphometric characteristics and baseline cardiac function of the adult mice (ICR
strain).
_________________________________________________________________________________________
_____________
Control
Group I
Group II
Group III
Group IV
(n = 6)
(n = 6)
(n = 6)
(n = 6)
(n = 6)
______________________________________________________________________________ ____________________________
Body Weight (g)
42.2 ± 1.3
37.0 ± 0.9
38.7 ± 2.1
41.5 ± 2.7
36.1 ± 1.3
Heart Wet Weight (mg)
258 ± 6
243 ± 16
242 ± 14
252 ± 18
258 ± 20
Heart Rate (bpm)
368 ± 23
340± 26
345 ± 23
368 ± 37
373± 17
Developed Force (g)
0.81 ± 0.19
1.06 ± 0.27
1.12 ± 0.12
1.09 ± 0.23
0.77 ± 0.16
Rate-Force Product (g x bpm)
308 ± 80
361 ± 109
372 ± 49
411 ± 107
287 ± 65
Coronary Flow (ml/min)
2.3 ± 0.2
2.3 ± 0.3
1.7 ± 0.1
2.1 ± 0.2
2.7 ± 0.3
___________________________________________________________________________________________________________

Values are mean ± SEM. No significant difference (P<0.05, one-way ANOVA) between
the groups were found for the listed parameters.
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Figure 7. Protocol for animal experiments depicting experimental groups, salicylic acid
(SA) level, ischemic condition and coronary effluent sample time points.
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which were not subjected to ischemia and used non-SA Krebs buffer (Farthing et al.,
2006). Group I consisted of six hearts which were not subjected to global cardiac
ischemia; however the Krebs buffer solution contained 1.0 mM SA to evaluate the effects
of the highest tested concentration of SA on ATP catabolism and PNP activity. Group II
consisted of six hearts which were subjected to global cardiac ischemia with the Krebs
buffer solution not containing SA to evaluate the effects of ischemic conditions on ATP
catabolic by-products. To determine if the effects of SA are dose-dependent in the hearts
undergoing global cardiac ischemia, Group III consisted of six hearts which were subjected
to Krebs buffer solution containing 0.1 mM SA and Group IV consisted of six hearts
subjected to 1.0 mM SA.
3.2.3 HPLC-UV Conditions and Mobile Phase
All instrument conditions were performed as previously reported (Farthing et al.,
2007). Briefly, the HPLC-UV method used a Phenomenex® Onyx™ monolithic C18
analytical column (20 cm x 4.6 mm I.D., 130 Å) and Onyx™ C18 guard column (5 cm x 4.6
mm I.D.) (Torrance CA, USA). The mobile phase gradient consisted of aqueous
trifluoroacetic acid (0.1% TFA in deionized water, pH 2.2, v/v) and methanol with time
course (1 to 20% methanol linear gradient over 10 min). The mobile phase flow-rate was
1.0 ml/min with operating pressure of ~84 bar at ambient column temperature. A 15 µl
direct injection of the Krebs buffer perfusate sample was made with optimal UV
wavelength absorption of 250 nm used for inosine and hypoxanthine detection.
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3.2.4

Data Computation and Statistics
The HPLC data acquisition and component computations were performed using

TotalChrom™ Workstation software (Perkin Elmer™, Norwalk, CT, USA). Statistics
utilizing ANOVA to compare the multi-group experimental results was performed using
MS Excel (Microsoft®, Seattle, WA, USA) and post hoc analysis (Dunnett, Tukey) using
JMP 6.0 (SAS Institute Inc., Cary, NC, USA) with α=0.05 and P<0.05 demonstrating
significance. The Dunnett post hoc analysis was performed to compare each experimental
test group’s mean result to a control group’s mean result. In addition, the Tukey post hoc
analysis was also performed as it compares each group’s mean result to each of the other
group’s mean result. However, it should be emphasized that for these non-parametric
analysis, the small sample size (n=6 each group) for these animal experiments may be a
limitation when interpreting the results. Correlation evaluation was performed using
GraphPad Prism 4 (San Diego, CA, USA). For determining total effluxed inosine, the area
under the curve (AUC) was calculated utilizing trapezoidal rule computations and MS
Excel on HPLC results (0 to 20 min time point perfusate samples).
3.3

Results and Discussion

3.3.1 Chromatography and Method Validation
Figure 8 shows representative chromatograms for: (A) low standard of
hypoxanthine (1.8 µM) and inosine (0.9 µM) in deionized water; (B) standard of
hypoxanthine (14.7 µM, RT ~5.2 min), uric acid (11.9 µM, RT ~5.6 in), xanthine (13.1
µM, RT ~6.7 min), adenosine (7.5 µM, RT ~10.3 min) and inosine (7.5 µM, RT ~10.5
min) in deionized water; (C) Group I (no ischemia + 1.0 mM SA) perfusate sample
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Figure 8. Chromatograms representing (A) low standard of 1.8 µM hypoxanthine (Hypo,
RT 5.2 min) and 0.9 µM inosine (Ino, RT 10.6 min) in deionized water, (B) standard of
14.7 µM hypoxanthine, 11.9 µM uric acid (UA, RT 5.6 min), 13.1 µM xanthine (Xan, RT
6.7 min), 7.5 µM adenosine (Adeno, RT 10.3 min) and 7.5 µM inosine in deionized water,
(C) Group I mouse perfusate sample (no ischemia and 1.0 mM SA), (D) Group II perfusate
sample (20 min global ischemia and no SA), (E) Group III mouse perfusate sample (20
min global ischemia and 0.1 mM SA) and (F) Group IV mouse perfusate sample (20 min
global ischemia and 1.0 mM SA).
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collected at 1 min of aerobic perfusion, (D) Group II (ischemia + 0 mM SA) perfusate
sample collected at 1 min of reperfusion; (E) Group III (ischemia + 0.1 mM SA) perfusate
sample collected at 1 min of reperfusion; and (F) Group IV (ischemia + 1.0 mM SA)
perfusate sample collected at 1 min of reperfusion.
As demonstrated by the chromatograms, the HPLC method provided sufficient
sensitivity (Figure 8A) and selectivity (Figure 8B) for each of the ATP catabolic byproducts. Figures 8C, 8D, 8E and 8F demonstrate how changes in experimental conditions
(ischemia and SA concentrations) resulted in increased concentrations of inosine and
hypoxanthine effluxed from the heart. Particularly Figures 8E and 8F demonstrate higher
levels of ATP catabolic by-products suggesting the presence of SA in the Krebs buffer
exacerbates ATP uncoupling only in the ischemic mouse hearts. It is also noteworthy that
the heart subjected to ischemia under 1.0 mM SA (Group IV, Figure 8F)
had elevated levels of ATP catabolic by-product adenosine, which is the nucleoside
precursor to inosine and indicative of the largest total amount of ATP catabolic byproducts effluxed due to the effect of 1.0 mM SA on the ischemic heart. All
chromatograms obtained from animal reperfusates using SA in the Krebs buffer solution
lacked detectable levels of xanthine and uric acid components, thus supporting published
research citing ASA and SA inhibitory effects on the XO enzyme (Carlin et al., 1985;
Masuoka et al., 2003).
Method validation was performed as described in our previous publication
(Farthing et al., 2007) and in summary, the method demonstrated sufficient linearity of the
calibration standards (inosine curve 0.9-18.6 µM, hypoxanthine curve 1.8-36.7 µM, with
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R>0.9990 for each component) and method detection limits of 0.4 µM (inosine) and 0.7
µM (hypoxanthine). Method accuracy and precision for inosine and hypoxanthine was
determined using quality control samples (n=15) with acceptable combined intra-day and
inter-day component accuracy (±6 % error) and precision (±8.1 % CV). To demonstrate
component stability, re-injections of the animal perfusate samples were made after sitting
on the HPLC autosampler overnight at lab ambient temperature and again after long term
storage. Both inosine and hypoxanthine in animal perfusate demonstrated excellent
stability overnight on the HPLC autosampler and for more than 6 months when stored at
-20°C.
3.3.2

Effect of Salicylic Acid on Purine Efflux
Table 7 lists mean (SEM) inosine and hypoxanthine concentrations for the mouse

hearts representing each of the 5 experimental groups. As shown in Figure 9, Control
group without both cardiac ischemia and SA (Farthing et al., 2006) and Group I (nonischemic hearts but using 1.0 mM SA, the highest tested SA concentration) did not have
detectable amounts of ATP catabolic by-products. However, inosine levels for Groups II,
III and IV (all underwent global ischemia) had significantly elevated total inosine efflux of
1,437±348, 3,872±900, and 12,575±3319 ng/mL/min respectively (mean ± SEM, Figure
9), i.e. Groups II (P<0.05), III (P<0.05), and IV (P<0.01) as compared with the Control
group (Dunnett test). These inosine results demonstrate that SA concentrations increased
ATP catabolism under our conditions of acute global cardiac ischemia with groups III and
IV mean total effluxed inosine levels potentiated above group II by approximately 2.7-fold
and 8.8-fold, respectively.
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Table 7. Table with mean (SEM) inosine and hypoxanthine concentrations and
inosine/hypoxanthine ratios under various experimental conditions (control and global
cardiac ischemia) and concentrations of salicylic acid in Krebs buffer (0, 0.1 and 1.0 mM).

Sample
Control
(n=6)

Ischemia
No

Group I
(n=6)

No

Group II
(n=6)

Yes

Group III
(n=6)

Yes

Group IV
(n=6)

Yes

Reperfusion
Time (min)
0
1
3
5
10
20
0
1
3
5
10
20
0
1
3
5
10
20
0
1
3
5
10
20
0
1
3
5
10
20

Mean
Hypoxanthine
[µM]
0
0
0
0
0
0
0
0
0
0
0
0
2.8
111.5
29.4
9.7
9.7
2.8
0
230.7
83.0
38.9
38.9
11.0
15.4
183.2
89.2
46.3
20.9
14.2

SEM
Hypoxanthine
0
0
0
0
0
0
0
0
0
0
0
0
2.0
0.6
0.6
2.0
2.0
2.0
0
0.7
0.4
1.4
1.4
1.4
1.5
1.1
1.2
1.4
1.4
1.5

Mean Inosine
[µM]
0
0
0
0
0
0
0
0
0
0
0
0
1.2
200.9
41.7
16.9
15.5
2.6
0
391.5
117.8
53.7
49.6
4.5
12.9
761.3
240.0
85.4
19.1
10.7

SEM
Inosine
0
0
0
0
0
0
0
0
0
0
0
0
2.0
0.6
0.6
1.0
1.2
1.2
0
0.5
0.4
0.8
1.0
1.4
1.5
1.1
1.5
1.6
1.3
1.5

Inosine/Hypoxanthine
ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.4
1.8
1.4
1.7
1.6
0.9
N/A
1.7
1.4
0
0
0
0.8
4.2
2.7
1.8
0.9
0.8

Krebs
Salicylic
Acid Level
0 mM SA

1.0 mM SA

0 mM SA

0.1 mM SA

1.0 mM SA
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Figure 9. Bar chart representing total effluxed inosine (mean + SEM) for control (Ctrl),
Group I, Group II, Group III and Group IV experimental conditions. Groups II, III and IV
demonstrated statistical significance (* is p<0.05, ** is p<0.01) from Ctrl (Dunnett test)
and Group I (Tukey test). Ctrl (no ischemia and no SA), Group I (no ischemia and 1.0 mM
SA), Group II (20 min global ischemia and no SA), Group III (20 min global ischemia and
0.1 mM SA) and Group IV (20 min global ischemia and 1.0 mM SA).

86
It should be noted that we did not observe any ATP catabolic by-products from
group I animals (1.0 mM SA and non-ischemic). Based on published work (NultonPersson et al., 2004; Cronstein et al., 1994), we suspected that in the presence of 1.0 mM
SA we might observe low concentrations of ATP catabolic by-products even under nonischemic conditions. However, we did not observe either inosine or hypoxanthine in
detectable levels from any perfusate samples from this experiment group. One possible
explanation is that these authors used cardiac mitochondrial preparations for their studies
and not the entire heart tissue as did our study. They reported 1.0 mM SA uncoupling
oxidative phosphorylation by approximately 20% (using oxygen electrode and αketoglutarate dehydrogenase enzyme analysis) which may not produce high enough
concentrations of ATP metabolites to activate the normally dormant adenosine deaminase
and PNP enzymes, thus inosine and hypoxanthine would not be produced and detected.
Using SA and ischemic conditions together would combine the effects of SA (ATP
decoupling) and ischemia (blocks ATP synthesis) and lead to significant reduction in
cellular ATP concentration and the potentiated effluxed levels of inosine observed in our
present study.
3.3.3

Effect of Salicylic Acid on Cardiac Function
Figure 10 bar charts (mean ± SEM) demonstrate the effects of SA on cardiac

functional parameters (DF, HR, RFP). No significant differences were found in HR for all
experimental conditions. For DF and RFP, significance (P<0.05, Tukey test) was
demonstrated between Groups III and IV relative to each other but neither group was
statistically different than control (Dunnett test). Cardiac DF and RFP were slightly
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Figure 10. Bar chart representing mean ± SEM for cardiac developed force (DF), heart rate
(HR) and rate-force product (RFP) at the end of 30 min reperfusion for each of the
experimental groups. Developed force and RFP on Groups III and IV demonstrated
statistical significance (* is p<0.05, Tukey test) between each other, however neither
demonstrated significance from control (Ctrl) (Dunnett test) nor Group I (Tukey test).
Control (no ischemia and no SA), Group I (no ischemia and 1.0 mM SA), Group II (20
min global ischemia and no SA), Group III (20 min global ischemia and 0.1 mM SA) and
Group IV (20 min global ischemia and 1.0 mM SA).
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increased (beneficial) at the 0.1 mM SA concentration, but adversely affected at 1.0 mM
SA. Theses results demonstrate that under conditions of acute global cardiac ischemia,
higher levels of SA in the Krebs buffer exhibited an increasing relationship on effluxed
inosine; however a beneficial then adverse effect on DF and RFP was observed. These
results have confirmed the previously reported positive inotropic effects of ASA on cardiac
contractility through inhibiting COX enzymes and in turn prostaglandin synthesis
(Karmazyn, 1986) and through its modulating effects on cellular calcium levels
(Molderings et al., 1987).
3.3.4 Non-Linear Relationship of Inosine Efflux and Cardiac Contractile Function
Following Ischemia
Figure 11 is a correlation plot which demonstrates the lack of correlation between
total effluxed inosine (in Groups II, III and IV) and DF or FRP, with r2 (coefficient of
determination) values of 0.52 and 0.59, respectively. This non-linear relationship can be
explained by an apparent beneficial effect of 0.1 mM SA on heart contractility, yet an
adverse effect at 1.0 mM SA, while total effluxed inosine increased with increasing SA
concentrations. Therefore, whereas the inosine efflux concentration could serve as a
sensitive biomarker for acute cardiac ischemia, it appears to be a poor predictor of the
individual post-ischemic cardiac functional recovery, at least in this ex vivo model.
3.3.5

Effect of Salicylic Acid on Purine Nucleoside Phosphorylase Activity
Figure 12 illustrates the ATP catabolic by-products resulting from acute cardiac

ischemic conditions. Normally dormant enzymes in heart tissue (e.g. adenosine
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Figure 11. Correlation plot demonstrating lack of significant linear correlation between
total effluxed inosine (AUC) and DF or RFP in the ischemic mouse hearts under various
SA concentrations (0, 0.1 and 1.0 mM). Group II (20 min global ischemia and no SA),
Group III (20 min global ischemia and 0.1 mM SA) and Group IV (20 min global ischemia
and 1.0 mM SA).
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deaminase, purine nucleoside phosphorylase) are activated due to cellular buildup of ATP
catabolic by-products (e.g. ADP, AMP). Under our experimental conditions, inosine and
hypoxanthine were the primary effluxed by-products of ATP catabolism. In observation of
the larger amounts of total inosine effluxed in our 1.0 mM SA perfusate samples, we
wanted to investigate if SA had a negative effect (inhibitory) on PNP enzyme activity
which might account for the potentiated effluxed inosine levels.
The PNP enzyme activity under ischemic conditions can be indirectly determined
by calculating the conversion of inosine to hypoxanthine ratio on each perfusate sample.
Table 7 lists the inosine [µM]/hypoxanthine [µM] (ino/hypo) conversion ratio for the
experimental groups. In Group II (ischemia, 0 mM SA), the ino/hypo mean conversion
ratio was approximately ~1.3. Under Group IV experimental conditions (ischemia, 1.0
mM SA), the ino/hypo conversion ratios were not constant with the perfusate sample
collected at 1 min of reperfusion having the largest ino/hypo ratio, and at the subsequent
time points returning to a more constant ino/hypo conversion ratio (~0.9) (Figure 13).
These results can be explained by two effects occurring simultaneously when using
both SA and ischemia conditions. Cardiac ischemic (anaerobic) conditions can cause ATP
catabolism as demonstrated in our previous work (Farthing et al., 2006), while SA has
been reported to cause decoupling of cardiac mitochondrial respiration (Nulton-Persson et
al., 2004). Both situations may contribute to the increase in ATP catabolic by-products as
heart muscle contractions require significant amounts of ATP as its primary energy source.
This leads to cellular buildups of ADP and AMP metabolic by-products as ATP is not able
to be regenerated (via salvage pathway) or synthesized, thus ATP catabolism occurs to
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eliminate the cellular buildup of by-products. As aerobic conditions to the heart tissue was
reestablished via reperfusion, the ino/hypo conversion ratio returns to a more constant
conversion ratio (e.g. ~0.9). The conversion ratio drops to zero as aerobic conditions
should deactivate ADA and PNP enzymes in the cardiac myocytes, thus inhibiting ATP
catabolism (Figure 13).
3.3.6

Potential Clinical Relevance
Since both ASA and SA have been reported to uncouple mitochondrial respiration

under aerobic conditions and in turn to inhibit ATP synthesis (Nulton-Persson et al., 2004)
and our current study demonstrates a potentiated ATP catabolism by SA under cardiac
ischemia, it is possible that current use of ASA for medical emergency treatment in acute
cardiac ischemic situations (e.g. acute MI) may potentially increase the ischemia-caused
ATP catabolism and inosine efflux.
While standardized doses of ASA (160 to 325 mg) are used to inhibit platelet
aggregation at the site of thrombus as part of the treatment for acute MI, the higher 325 mg
dose equates to a potential Cmax of 67 µM acetyl salicylic acid and 188 µM salicylic acid
blood concentrations. Even with its significant protein binding (e.g. albumin), the
augmented free drug levels of ASA and its metabolite SA may have an inhibitory effect on
cardiac ATP production during the periods of acute cardiac ischemia. The SA-induced
enhancement of inosine efflux should also be taken into consideration when we analyze
and interpret the patient’s plasma inosine level as a potential biomarker for acute cardiac
ischemia (Farthing et al. 2006, 2007).
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Figure 13. Plot of inosine [µM] to hypoxanthine[µM] (ino/hypo) conversion ratio versus
reperfusion time (min). The plot represents mean data from experimental conditions.
Ino/hypo conversion ratio is highest in the 1 min reperfusion sample and returns to a
constant ratio before dropping as aerobic conditions presumably deactivate ADA and PNP
enzymes in the cardiac myocytes.

94
Whereas there are certainly positive benefits associated with using ASA as part of
the treatment for acute MI patients to inhibit platelet aggregation at the site of thrombus,
higher doses of ASA used for other medical conditions including analgesia (0.5 mM
plasma salicylate) and rheumatoid arthritis (1.5 to 2.5 mM plasma salicylate) may actually
aggravate the ischemic effects on heart tissue metabolism and ventricular contractile
function, if the patients who have been using higher dose of ASA suddenly encounter acute
cardiac ischemic events. This animal research on isolated mouse hearts utilized SA levels
of 0.1 and 1.0 mM, which were slightly lower but similar to expected blood concentrations
in human patients utilizing aspirin as treatment for the above described medical conditions
(e.g. acute MI, rheumatoid arthritis). We suggest that further laboratory and clinical
studies are warranted on the apparent adverse effects of higher concentrations of ASA and
SA on ATP catabolism under acute cardiac ischemia, given the knowledge of how
widespread ASA is used for its other medical benefits (e.g. analgesia, rheumatoid arthritis)
and the possibility of those patients one day experiencing an acute cardiac
ischemic event.
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CHAPTER 4. Human Plasma Sample Evaluation, “An HPLC method for
determination of inosine and hypoxanthine in human plasma from
healthy volunteers and patients presenting with potential acute cardiac
ischemia”

4.1

Introduction
The mouse model results from Chapter 2 research demonstrated significant levels

of inosine and elevated levels of hypoxanthine effluxed from cardiac tissue subjected to
constant conditions of oxidative stress (e.g. acute cardiac ischemia or myocardial
infarction) (Farthing et al., 2006). For this chapter of research, the HPLC method from
Chapter 2 was modified and validated for the evaluation of human plasma samples, which
are significantly more complex than Krebs perfusate samples from Chapter 2.

The

purpose for the development of a plasma test method was to facilitate evaluation of the
research hypothesis that non-traumatic chest pain patients potentially undergoing acute
cardiac ischemia; should have elevated blood levels of ATP catabolic products (e.g.
inosine and hypoxanthine) in their bloodstream, until medical treatment can succeed in
restoring adequate blood flow to the oxygen deprived myocardium.
Samples representing healthy individuals, hospital non-traumatic chest pain
patients as well as other common vascular disease (e.g. congestive heart failure (CHF),
hypertension (HT)) conditions were evaluated for inosine and hypoxanthine concentration
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levels. In addition, subject matched sample sets comprised of consecutive blood draws for
plasma (heparin) and serum separator tube (SST), from healthy normal individuals were
evaluated to determine if the blood draw matrix (e.g. anticoagulants, SST gel) affected
inosine and hypoxanthine concentrations.
Current test methods for endogenous cardiac biomarkers (e.g. cardiac troponin I,
creatine kinase-MB and myoglobin) include LC-MS analysis (Bunk et al., 2000; Mayr et
al. 2006) and fluorescence immunoassay (Apple et al., 1999; Heeschen et al., 1999; Apple
et al., 2000; McCord et al., 2001); however elevation of these protein biomarkers reflect
some level of myocardial necrosis, and are typically elevated in a diagnostic range several
hours after acute myocardial infarction. Current methods for plasma level measurement of
selected ATP catabolic by-products such as inosine, hypoxanthine, xanthine and uric acid,
in plasma utilize HPLC-UV with sample preparation steps including solid phase extraction
(Feng et al., 2000), protein precipitations (e.g. ethanol or TCA) as well as some methods
requiring use of an internal standard (Boulieu et al., 1983; Boulieu et al., 1984). HPLC
with ion pairing reagents (Scott et al., 1992; Furst et al., 1992; Tavazzi et al., 2005) or
protein precipitation and enzyme catalyzed luminescence detection (Jabs et al., 1990) have
also been used. One HPLC method utilized centrifugal filtration for sample preparation;
however their method did not completely resolve hypoxanthine and xanthine components
at concentrations five times lower than our patient hypoxanthine concentrations, and with
reported column degradation after three months of use (Severini et al., 1987).
None of these techniques, however, offers as simple a determination for inosine
and hypoxanthine (can also evaluate uric acid, adenosine, and xanthine) in human plasma
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as the method detailed in this chapter of research. The method utilizes centrifugal
membrane filter technology and does not require the use of an internal standard. In
addition, this method employs a recently introduced HPLC column technology (Onyx™
monolithic column, Phenomenex® Inc. 2005 market introduction) (Phenomenex Inc.),
which provided sufficient component resolution and sensitivity for measurement of inosine
and hypoxanthine in human plasma samples, from healthy volunteers and emergency
department patients presenting with chest pain with and without acute cardiac ischemia.
4.2

Human Plasma and Serum Sample Procurement
To obtain human plasma samples used for analytical evaluations (HPLC-UV and

Luminometer), approvals from Virginia Commonwealth University (VCU) Institutional
Review Board (IRB) (Appendix C) and Chippenham Hospital (Richmond, VA) Clinical
Chemistry Department were obtained. Plasma samples (lithium heparin) from normal
healthy individuals (non-symptomatic for cardiac disease) were acquired from VCU
Medical Center and plasma samples (lithium heparin) from non-traumatic chest pain
patients were acquired from Chippenham Hospital Clinical Chemistry Department. All
obtained samples were frozen (-20°C or below) after draw and prior to analysis.
In addition, purchased human plasma (EDTA and lithium heparin anticoagulant)
from cardiac diseased patients (e.g. hypertension, acute myocardial infarction), human
blank plasma (lithium heparin anticoagulant) and serum samples (SST and non-SST) were
commercially obtained from a FDA certified biorepository, ProMedDx (Norton, MA,
USA) (Appendix D), which utilized an IRB protocol for their sample procurements. The
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ProMedDx samples were stored frozen (-20°C or below) after draw and during storage
prior to analytical evaluations.

4.3

HPLC-UV Assay Development

4.3.1

Experimental

4.3.1.1 Chemicals and Blank Plasma
Hypoxanthine and xanthine were purchased from Acros Organics (Fair Lawn, NJ,
USA) and adenosine, inosine and uric acid were purchased from Sigma-Aldrich (St. Louis,
MO, USA) with all chemicals being ACS reagent grade or higher purity. For mobile phase
preparation, trifluoroacetic acid (TFA) was reagent grade, methanol was Optima HPLC
grade and both were purchased from Fisher Scientific (Fair Lawn, NJ, USA). Ultrapure
distilled and deionized water (18 MΩ-cm) used for all HPLC work was prepared in-house
using PureLab® Ultra water purification system (US Filter, Lowell, MA, USA) and 0.2 µm
filtered prior to use. Blood bank human blank plasma (acid citrate) used for preparation of
controls was provided by VCU Medical Center, Richmond, VA USA.
4.3.1.2 HPLC Equipment and Mobile Phase
The HPLC-DAD (diode array detector) equipment consisted of a Hewlett Packard
(HP) Model 1090 HPLC system (Agilent Technologies, Palo Alto, CA, USA). The
analytical column used was a Phenomenex® Onyx™ monolithic C18, 20 cm x 4.6 mm I.D.,
130 Å column coupled to an Onyx™ C18 guard column, 5 cm x 4.6 mm I.D. (Torrance CA,
USA). The guard column was replaced after each analytical run of approximately 50
samples. The mobile phase consisted of aqueous trifluoroacetic acid (0.1% TFA in
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deionized water, pH 2.2, v/v) and methanol gradient. The mobile phase gradient was
programmed with time course as follows (99:1 0.1% TFA in deionized water:methanol,
v/v at 0 min and held for 3 min; 70:20 0.1% TFA in deionized water:methanol, v/v at 10
min; 5:90 0.1% TFA in deionized water:methanol, v/v at 11 min and held 2 min, and 99:1
0.1% TFA in deionized water:methanol, v/v at 14 min).
The mobile phase was continuously degassed using helium sparging and used at a
flow-rate of 1.0 ml/min. Typical HPLC operating pressure at gradient time 0 min
conditions was approximately 84 bar with ambient column temperature. An injection
volume of 15 µl of the prepared plasma sample was accomplished using the HP Model
1090 autosampler. Component detection was achieved using the HP Model 1090 DAD
detector with data collection at the optimal UV wavelength absorption of 250 nm for both
inosine and hypoxanthine. The detector was operated at high sensitivity set point with a 1
s response time. A 345 kPa back-pressure regulator (SSI, State College, PA, USA) was
coupled to the detector outlet to prevent mobile phase out-gassing. Data acquisition and
component computations were performed using TotalChrom™ Workstation software
(Perkin Elmer™, Norwalk, CT, USA).
4.3.1.3 Standard and Control Preparation, Freeze-Thaw Study
Stock standards of adenosine (374.2 µM), inosine (372.8 µM), hypoxanthine (734.7
µM), xanthine (657.4 µM) and uric acid (594.8 µM) were prepared in deionized water and
stored at 4°C. Working standards to establish HPLC retention times of adenosine (9.4
µM), xanthine (16.4 µM) and uric acid (14.9 µM) components were prepared in deionized
water. Working standards of inosine (0.9, 1.9, 3.7, 11.2 and 18.6 µM) and hypoxanthine
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(1.8, 3.7, 7.3, 22.0 and 36.7 µM) were prepared in deionized water. All working standards
were stored at -70°C and stable for at least 6 months. Working controls of inosine (0.9, 7.5
and 14.9 µM) and hypoxanthine (1.8, 14.7 and 29.4 µM) were prepared using pooled
hospital blood bank blank plasma (n=3 donated lots) which were evaluated individually
and confirmed to lack detectable levels of inosine and hypoxanthine components.
It is possible the levels of inosine and hypoxanthine in blood bank plasma were not
detectable due to the time (>10 days) the plasma was stored refrigerated (4°C) prior to
expiration and availability for laboratory experimental use. Without freezing the plasma or
utilizing plasma enzyme inhibitors, xanthine oxidase and purine nucleoside phosphorylase
found in plasma may metabolize the normally low levels of inosine and hypoxanthine to
their end product uric acid. Following preparation of control samples, they were
immediately frozen at -70°C, to prevent endogenous plasma purine nucleoside
phosphoryase from converting inosine to hypoxanthine prior to formal sample analysis.
To demonstrate inosine and hypoxanthine freeze-thaw stability, control samples at
each concentration were freeze-thawed (n=2 times) and evaluated by HPLC for
degradation. The lack of inosine and hypoxanthine degradation from freeze-thaw from
-70˚C was demonstrated by inosine and hypoxanthine concentrations being consistent
(<6.0% error) with the results from the accuracy and precision evaluation (Table 8).
4.3.1.4 Sample Conditions
Following hospital approval, blood was obtained from hospital emergency room
patients (n=20), in vacutainer™ tubes containing plasma (lithium heparin) as per hospital
emergency room protocols for patients presenting with non-traumatic chest pain and
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potential MI or acute myocardial ischemia. Sample tubes were centrifuged at ~1000 g for
10 min with plasma drawn off and split into tubes for hospital clinical testing and one tube
immediately frozen at -20°C (transferred to -70°C for storage) for inosine and
hypoxanthine analysis. Plasma (lithium heparin) samples from healthy blood donors (male
and female, both genders >18 years of age) were purchased from ProMedDx (Norton, MA,
USA) which used an IRB approved specimen collection protocol and stored frozen at 70°C. Prior to HPLC analysis, plasma samples were thawed to ambient temperature,
mixed thoroughly by inversion and centrifuged at 1000 g for 10 min to eliminate fibrous
material.
4.3.1.5 Sample Preparation
Samples were prepared for HPLC analysis by pipetting 250 μl of plasma into a
polypropylene Microcon® YM-10 (10,000 molecular weight cutoff, MWCO) centrifugal
filter tube (Millipore, Bedford MA, USA). The sample tubes were capped and centrifuged
at 14,000 g for 15 min at ambient lab temperature. The clear filtrates were transferred to
deactivated glass HPLC autosampler vials (Waters®, Milford MA, USA) with 15 μl
injected into the HPLC system for analysis.
4.3.2

Results and Discussion

4.3.2.1 HPLC Conditions Optimizations
Several types of C18 columns were evaluated for resolving adenosine, inosine,
hypoxanthine, xanthine and uric acid from other plasma components. Due to minimal
sample preparation using the centrifugal membrane filter, the ideal HPLC column should
have high efficiency for resolving inosine and hypoxanthine components from components
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in the plasma matrix. Conventional HPLC columns such as Synergi Polar-RP C18 (15 cm
x 3.0 mm ID x 4 µm packing) and Hypersil ODS C18 (15 cm x 3.2 mm ID x 3 µm packing)
were evaluated versus the recently marketed HPLC column technology, the Onyx
monolithic C18 column (10 cm x 4.6 mm ID).
The monolithic column provided superior chromatographic resolution of
components as described later in section 4.3.2.4 with a low system backpressure of
approximately 84 bar (gradient time zero conditions and flow rate of 1 ml/min). It should
be emphasized that both conventional HPLC columns were evaluated at operating flow
rates of ~0.6 ml/min and with system pressures that were approximately twice as high as
when using the monolithic column. The supplier of the monolithic column cited
advantages of high component efficiencies (resolution) and low system backpressure with
use of the new monolithic column technology. We observed that both of these stated
advantages over the two conventional mid-bore diameter HPLC columns evaluated were
clearly demonstrated. The mobile phase aqueous component, 0.1% TFA in deionized
water, provided a pH of 2.2 which also provided good peak shape (e.g. uric acid
component, pKa ~5.8) from components of interest from the endogenous plasma
components (MW <10,000 Da) obtained from the YM-10 sample preparation.
Optimization and adjustment of the acid strength improved the separation between
hypoxanthine (RT 5.2 min) and uric acid (RT 5.7 min). Initial use of aqueous 0.05% TFA
did not provide component baseline resolution while aqueous 0.1% TFA offered complete
component baseline resolution at the expense of increased column retention times. The
mobile phase organic modifiers (e.g. acetonitrile versus methanol) were evaluated to
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determine which organic solvent would provide the best chromatographic separation from
endogenous plasma components and at the same time being most cost effective. Methanol
was chosen as the organic modifier as it provided symmetrical component peak shapes and
good selectivity from other endogenous plasma components; however the HPLC system
backpressure was somewhat higher when using methanol with the methanol gradient
increasing from 1 to 90%. Methanol is also more cost effective for routine HPLC analysis
because of its lower procurement cost.
A mobile phase gradient was used for reproducible separations of the structurally
similar purines (hypoxanthine, uric acid) and nucleosides (inosine, adenosine). Since the
mobile phase organic constituent is critical to controlling component elution times (initial
1% methanol composition at gradient time zero), the use of protein precipitation technique
using solvents such as acetonitrile or methanol (typically 1:1 or 2:1, organic:plasma ratio)
was eliminated from consideration.. The structurally similar components injected using
organic solvent precipitation were not chromatographically resolved due to band
broadening effects from the added organic modifier. Different column oven temperatures
(e.g. ambient lab of 20°C, 30°C and 40°C) were evaluated without significant
chromatographic improvement (component resolution, peak shape), thus ambient
temperature was utilized for the analysis. At higher column temperatures (e.g. 40°C),
component co-elution for both early (hypoxanthine, uric acid) and late components
(inosine, adenosine) was observed.
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4.3.2.2 Linearity, Limits of Quantitation and Detection, Computations
The plasma method was linear throughout the concentration range of 0.9 to 18.6
µM for inosine (mean correlation coefficient of 0.9991, n=10) and 1.8 to 36.7 µM
hypoxanthine (mean correlation coefficient of 0.9998, n=10) with all standard backcalculated values within 5% of their nominal amount. The limit of detection (LOD) for
inosine (0.4 µM) and hypoxanthine (0.7 µM) was determined using a fortified amount of
each component in pooled blood blank plasma (n=3 each) and calculation from each
component’s standard curve (component peak heights had greater than 3 times s/n than
blank plasma background). For plasma component calculations and reporting results,
normal linear regression utilizing external standardization and peak height was used with
the lowest calibration standard as the limit of quantification (defined as combined accuracy
and precision within 20% of the nominal amount).
4.3.2.3 Accuracy, Precision and Recovery
The accuracy and precision for the method was determined by evaluation of
replicate prepared plasma control samples (inosine at 0.9, 7.5, 14.9 µM and hypoxanthine
at 1.8, 14.7, and 29.4 µM) (Table 8). The combined intra-day (within day) and inter-day
(between day) accuracy of the method was reported as the percent error of nominal
fortified amounts versus measured component concentrations. The combined intra-day
and inter-day precision of the method was reported as percent relative standard deviation
(% RSD). The method demonstrated sufficient accuracy (±6%) and precision (±8.1) for
both components in plasma (n=15 at each component concentration level). Absolute
recovery for the plasma method was evaluated by comparing the extracted fortified control
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Table 8
Combined intra and inter-day accuracy and precision for inosine and hypoxanthine in
plasma controls. Controls demonstrated excellent accuracy ±6% and precision ±8.1%
throughout the plasma concentration range.

Fortified

Calculated Mean

Concentration (µM)

Concentration (µM)

n=15

n=15

Inosine

0.93

Inosine

Component

% Error

% RSD

0.91

-2.8

8.1

7.5

7.3

-1.7

4.9

Inosine

14.9

14.6

-2.2

3.6

Hypoxanthine

1.84

1.95

6.0

7.5

Hypoxanthine

14.7

15.0

2.2

5.5

Hypoxanthine

29.4

28.9

-1.7

2.2
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samples prepared in pooled blood blank plasma versus unextracted standards prepared in
deionized water (n=3). The absolute recovery for the plasma method was determined to be
>98% for both inosine and hypoxanthine. In addition, the standards and controls used for
all HPLC analysis were prepared and handled identical to patient and volunteer subject
samples, thus controlling for potential errors in sample handling, micropipetting and YM10 component extraction recovery.
4.3.2.4 Chromatography
Figure 14 illustrates chromatograms of 14.7 µM hypoxanthine (RT ~5.3 min), 11.9
µM uric acid (RT ~5.8 min), 13.1 µM xanthine (RT ~7.2 min), 7.5 µM adenosine (RT
~10.7 min) and 7.5 µM inosine. patient. (RT ~10.9 min) in deionized water for marking
component retention times; limit of quantitation and lowest plasma standard of 1.84 µM
hypoxanthine and 0.93 µM inosine; pooled blank plasma (acid citrate) from the VCU
Health Systems Hospital blood bank; prepared plasma (lithium heparin) from a healthy
female subject; and prepared plasma (lithium) from a hospital emergency room female
patient exhibiting symptoms of chest pain and acute myocardial ischemia (Figures A, B, C,
D and E, respectively).
The method demonstrated good component chromatographic selectivity with no
endogenous plasma interferences at the retention times of hypoxanthine and inosine. This
method also provided sufficient sensitivity for both components of interest using
conventional UV detection with an analytical run time of ~21 min (allows mobile phase
gradient equilibration). To extend column lifetime, the analytical column was flushed after
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Figure 14. Chromatograms illustrating (a) 14.7 µM hypoxanthine (RT ~5.3 min), 11.9 µM
uric acid (RT ~5.8 min), 13.1 µM xanthine (RT ~7.2 min), 7.5 µM adenosine (RT ~10.7
min) and 7.5 µM inosine (RT ~10.9 min) in deionized water, (b) low standard of 1.84 µM
hypoxanthine and 0.93 µM inosine in blank plasma, (c) blank plasma, (d) plasma sample
from healthy female subject and (e) plasma sample from hospital emergency room female
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each analytical run (~50 injections) for 1 h at 1.0 ml/min with acetonitrile: deionized water
(90:10, v/v) to eliminate potential retained non-polar substances from the column.
4.3.2.5 Sample Preparation Optimization and Filtrate Stability
Sample preparation evaluations using protein precipitation and centrifugal
membrane filters were conducted. As previously described in Section 4.3.2.1, organic
solvent precipitation was not useful due to resulting poor chromatographic resolution of
structurally similar components. TCA (trichloroacetic acid) was not evaluated due to the
hazards of using the strong acid and the resulting sample dilution effect potentially
affecting overall method sensitivity. The centrifugal membrane filter is commonly used to
concentrate peptides, proteins and nucleic acids for proteonomic and genomic
determinations [Microcon Centrifugal Filter Devices].
Since the molecular weights of our components are all less than 300 Da, our
approach to using this technique was to inject the filtrate which would contain the low
molecular weight components that transfers across theYM-3 or YM-10 cellulose
membrane cutoff filters. This essentially removes most peptides and all proteins from the
sample to be injected as they are retained by the cellulose membrane cutoff filter, thus
improving method selectivity. Method sensitivity is also improved because there is no
sample dilution effect since there is no solvent added.
Evaluations to optimize sample preparation conditions using the YM-10 (10,000 Da
MWCO) and YM-3 (3,000 Da MWCO) centrifugal filter were conducted. With the
centrifugal force set at 14,000 g (recommended by YM-10 supplier) and using 250 uL of
prepared plasma control samples, the centrifuge spin time was varied from 5, 15, 30 and 60
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min. The five min spin time did not provide enough time to adequately separate plasma
proteins from the aqueous matrix (salts, small peptides and substances less than 10,000 Da)
with an insufficient amount of sample filtrate recovered. The 15, 30 and 60 min
centrifugal spin times resulted in maximum recovery of sample filtrate. However the 60
min spin filtrate samples were significantly warmer than ambient lab temperature most
likely due to warming effects of the sample tubes friction with air from the centrifugal
spin. Thus to eliminate potential component degradation due to heat from spinning 60 min
and to shorten sample preparation time, a spin time of 15 min was used for all analyses as
described in section 3.3.
Results for the YM-3 filter evaluation demonstrated longer spin times were required
(~45 to 60 min) at 14,000 g versus the 15 min spin using the YM-10 filter. The YM-3
filtrate did not offer better filtration of smaller plasma peptides (<10K Da), as observed on
chromatograms, than was already achieved using the YM-10 filter. However, using either
YM-3 or YM-10 filter effectively removed the purine nucleoside phosphorylase enzyme
(nominal weight ~90-94 KDa protein, [Cook et al., 1981; Osborne, 1980]) thus eliminating
the potential for inosine to hypoxanthine metabolism in the sample filtrate. The filtrates
were stored frozen (-70˚C) after HPLC analysis with both inosine and hypoxanthine
components demonstrating stability for greater than 3 months.
4.3.2.6 Plasma Purine Nucleoside Phosphorylase Activity
Purine nucleoside phosphorylase (PNP, EC 2.4.2.1) is an enzyme that rapidly
metabolizes inosine to hypoxanthine in blood (t½ <5 min due to red blood cells). This
enzyme has low activity in plasma and is normally found in human cardiac muscle, GI
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tract, spleen, brain and red blood cells [Viegas et al., 2000; Yamamoto et al., 1995].
Therefore, to better estimate an ischemic heart’s effluxed inosine during periods of acute
cardiac oxidative stress, venous blood samples should be kept cold (ice) and prepared
immediately. Either the blood sample should be immediately inhibited (e.g. peldesine,
competitive inhibitor (Viegas et al., 2000)) or the metabolite hypoxanthine should be
simultaneously determined with inosine to better estimate the level of acute cardiac
ischemia.
In whole blood or plasma samples, hypoxanthine will not be further metabolized to
xanthine as the human enzyme xanthine oxidase (XO), which is require for hypoxanthine
to xanthine conversion, has low activity in plasma (Yamamoto et al., 1996) and is typically
found in human tissue (liver, small intestine) and other bodily fluids (milk and colostrum).
A plasma (heparinized) sample is recommended for inosine and hypoxanthine
determination in that the approximate 30 min clot time required for a serum sample would
allow significant conversion of inosine to hypoxanthine in the collection tube, which
would contain PNP from the red blood cell and plasma matrix.
Several evaluations (n=3 samples at each condition) were performed to evaluate
inosine metabolism by PNP activity in plasma stored at 4˚C (refrigerator), -20˚C and
-70˚C. Results of the evaluation can be seen in Figure 15; plasma fortified with inosine
only at 7.46 µM and without PNP enzyme inhibitor is metabolized rapidly to hypoxanthine
(~70% in 24 hrs); plasma fortified with 0.93 µM of inosine and 1.84 µM hypoxanthine and
without PNP enzyme inhibitor is also metabolized rapidly to hypoxanthine (~70% in 24
hrs); however the plasma fortified with 7.46 µM of inosine and 14.69 µM hypoxanthine

112

o

% Inosine Remaining

Graph of Plasma Inosine Conversion at 4 Celsius
100
90
80
70
60
50
40
30
20
10
0

0.93 µM Ino, 1.84 µM
Hypo
7.46 µM Ino, 14.69 µM
Hypo
7.46 µM Ino only

0

24

48

72

Refrigeration Time (hrs)

Figure 15. Graph of mean percent inosine remaining after plasma PNP metabolism when
stored at 4˚C. Square symbols represent fortified amounts of 7.46 µM inosine and
14.69 µM hypoxanthine in blank plasma (n=3), diamond symbols represent fortified
amounts of 0.93 µM inosine and 1.84 µM hypoxanthine in blank plasma (n=3), and
triangle symbols represent fortified amount of 7.46 µM inosine only in blank plasma
(n=3).
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and without a PNP enzyme inhibitor, is metabolized less rapidly to hypoxanthine (~30% in
24 hrs) and slightly less than 50% after 72 hrs. Results of storing fortified plasma samples
at -20˚C immediately after preparation indicated a reduced rate of inosine to hypoxanthine
conversion (~30% after 8 months) with storage at -70˚C almost completely deactivating
the PNP enzyme (<5% inosine conversion after 3 months). A possible explanation for the
plasma hypoxanthine-concentration dependence for the conversion rate of inosine to
hypoxanthine, would be product inhibition (PNP Keq≈0.04 mM) (Brenda Enzyme
Database). This low Keq indicates that thermodynamically, inosine synthesis is favored
over product conversion to hypoxanthine.
When the venous sample plasma concentration of hypoxanthine is present at higher
levels (e.g. 14.69 µM), the conversion of inosine to hypoxanthine by plasma PNP
decreases in the absence of significant XO enzyme activity, which converts hypoxanthine
to xanthine and uric acid for biological elimination (therefore XO activity ultimately
increases PNP activity as it reduces hypoxanthine product inhibition of PNP). It was also
determined that the total amount of inosine and hypoxanthine fortified into the pooled
plasma was recovered, thus verifying the lack of significant XO activity in human plasma
and supports our recommendation of simultaneous determination of both inosine and
hypoxanthine components.
A preliminary investigation to show the utility of the method is shown in Figures
14D (healthy control with 1.3 µM inosine and 2.74 µM hypoxanthine) and 14E (acute
cardiac ischemia patient with 2.39 µM inosine and 29.3 µM hypoxanthine). These figures
demonstrate an increase in both inosine and hypoxanthine concentrations (as well as final
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ATP catabolic by-product uric acid) in one patient having presented with non-traumatic
chest pain and undergoing evaluation for acute cardiac ischemia. Figure 16 demonstrates
significant levels (P<0.05) of inosine, hypoxanthine and a combined total inosine plus
hypoxanthine concentration level in plasma from ED non-traumatic chest pain patients and
healthy normal controls.
It is important to discuss the time course of the ED patient’s blood sample draw.
These patients arrive at the hospital emergency department with the chief complaint of
non-traumatic chest pain. Each patient’s time of the non-traumatic chest pain may vary
(minutes to hours) depending on the severity of their chest pain. Although the plasma
samples from the ED that were evaluated for this research represent each patient’s first
blood sample drawn for standard hospital clinical chemistry analysis (e.g. troponin I, CKMB), the samples themselves represent a range of time (minutes to hours) of potential
patient acute cardiac ischemia. Therefore, the interpretation of these ED results may have
this as a potential confounding factor or limitation.
4.4

Human Plasma (Heparin) versus Serum (SST) Sample Evaluation
Using the validated HPLC-UV method as described in Section 4.3, an evaluation

was performed on commercially purchased human plasma (heparin) and serum (SST)
samples. There are many techniques used for the specimen collection of biological fluids
(e.g. blood component). Examples are collection of plasma, serum or serum using an inert
gel barrier (SST) etc. As reproducibility of test results is a critical method validation
parameter, it becomes important to determine the proper specimen matrix for analysis and
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Figure 16. Chart depicting inosine, hypoxanthine, and total inosine plus hypoxanthine
concentrations (mean + SEM) in plasma from ED non-traumatic chest pain patients and
healthy normal individuals.
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to determine if the sample collection matrix affects the component(s) of interest (e.g.
resulting in artifacts in component concentrations) (Magee, 2005).
For this research, plasma (lithium) was initially selected for evaluation as many US
hospitals typically use plasma for measurement of cTnI and CK-MB analysis (e.g.
Chippenham Hospital). Serum (SST) is also being evaluated to investigate why one past
research group (Kock et al., 1994) reported hypoxanthine levels which were not
statistically significant in their patients that were undergoing acute myocardial infarction
and other ischemic diseases. As this research reports elevated levels of inosine and
significant levels of hypoxanthine in plasma from non-traumatic chest pain patients from a
local hospital emergency department, it is important to determine and explain how the
differences in reported hypoxanthine concentrations exist (if possible) between Kock et al.
and this research since we evaluated similar type of patients (e.g. acute cardiac ischemia).
Studies on sample collection matrices effects have been performed by other
investigators with reported differences in analyte levels based on the sample matrix
(Doumas, 1989), thereby necessitating this matrix effect study. Samples were acquired
from normal healthy volunteers (n=6) from a local blood bank (contracted with ProMedDx
for this sample requirement), with each subject’s blood acquisition being obtained
sequentially (first serum SST vacutainer sample draw followed by heparin vacutainer
sample draw), to minimize potential inosine and hypoxanthine concentration level changes
with time and phlebotomy techniques. When drawing multiple sample types from the
same subject, sample order of draw is documented as red top (serum) prior to green top
(heparin) to prevent potential anti-coagulant (heparin) contamination in the serum sample
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(ABP, Inc. 2004). Per ProMedDx, all collected samples were processed and handled
according to BD Vacutainer® inserts (e.g. centrifugation at 1200 g for 15 min) (BD
Vacutainer®, 2007), with the serum SST sample taken first followed by the heparin sample
(prevents potential anticoagulant carryover effect).
As some biomarkers are diurnal and time sensitive (e.g. some endogenous
hormones and proteins (e.g. CRP)), it supports the importance of requiring sequential
samples for this small study to eliminate potential errors, as inosine and hypoxanthine are
also endogenous to plasma and may possibly fluctuate throughout the day. After thawing
samples to ambient temperature, each was prepared using the 30K centrifugal membrane
filter and micro-centrifuged at 14,000 x g for 5 min, with all preparations analyzed by
HPLC (single injection of each sample) on the same analytical run date.
As demonstrated in Figure 17, there were differences observed in the hypoxanthine
concentrations from the same subject, with the serum (SST) samples generally higher in
hypoxanthine concentrations. A possible reason for observing the higher hypoxanthine
levels when using serum (SST) can be caused by red blood cell hemolysis during
preparation. It is also known that hemolysis is a common occurrence when using serum
samples (Arzoumanian, 2003) with another published article reporting significant
differences between 10 of 17 plasma and serum measured analytes (Hrubec et al., 2002).
When using the SST tube for collection, the BD package insert directions state to
gently invert the tube 5 times and let the tube sit 30 min prior to centrifugation. During
this time period, the blood clots (as no anticoagulant is used) with a formed thrombus.
With centrifugation, the formed thrombus remains near the bottom of the tube with the
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Hypoxanthine Concentration versus Sample Type
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Figure 17. Bar chart depicting differences in hypoxanthine concentrations between plasma
(lithium heparin) and serum (SST) from normal healthy individuals. Overall, SST samples
demonstrated ~19% positive bias relative to the plasma (lithium heparin) samples.
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other matrix components migrating upwards and around the inert gel (found initially at the
bottom of the tube but migrates upwards based on material density).
It is feasible that during this clotting time and subsequent centrifugation step, that
some red blood cells may leak some of its contents or hemolyze (rupture) due to
mechanical deformation, which has been recently reported with RBC (Sprague et al., 2001,
Sprague et al., 1996). It has also been reported that inside red blood cells, ATP is typically
found in significant amounts (mM levels) as the RBC also functions as an ATP storage
vesicle (Dietrich et al., 2000). If ATP is released from the RBC into the blood sample
matrix, it is enzymatically converted several times to form hypoxanthine (Heptinstall et al.,
2005, Coade et al., 1989), which may cause falsely elevated hypoxanthine results (artifact).
4.5

Other Cardiovascular Disease Matched Sample Set Evaluations
Further investigations into the effect of sample matrix were performed using

additional commercially purchased matched sample sets (contract with ProMedDx for
n=10 matched sets for each requested sample group). For this study, additional normal
healthy (non-symptomatic for ischemic cardiac disease) individual samples of plasma
(heparin) and serum (no gel) were collected and frozen at -20°C. The results of these
additional normal individuals can be used for comparison to the results obtained in Section
4.4 (i.e. healthy normals serum with gel (SST) versus healthy normals serum without gel).
In addition, matched sample sets representing two cardiovascular disease states
(e.g. hypertension, acute myocardial infarction) were also purchased from ProMedDx for
evaluation to determine patient basal concentrations of inosine and hypoxanthine in these
two cardiovascular disease states; however these matched sample sets were only available
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in plasma (heparin) and serum (SST). The plasma (lithium) and serum (SST) samples
from hypertension and acute myocardial infarction patients were collected at a hospital in
contractual agreement with ProMedDx with serum (SST) being the hospital normal sample
protocol for collecting serum samples and the collected samples frozen at -20°C prior to
HPLC-UV analysis. Clinical diagnosis and demographic information (e.g. age, gender,
medications) on patients with hypertension and acute myocardial infarction were provided
by the hospital where the matched sample sets were obtained.
Appendix D list the sample sets and HPLC-UV results for this section. Several
observations can be seen from the results. The matched sets for normal healthy individuals
had similar plasma and serum (without the inert gel, not SST) concentrations for inosine
and hypoxanthine. These results suggest that the initial results from using serum (SST)
from normal healthy individuals may have gel contributed artifacts affecting the
component concentrations (more notably hypoxanthine). In addition, the matched set
samples from hypertension and acute myocardial infarction had notable differences in
plasma and serum (SST) concentrations, somewhat for inosine but mainly for
hypoxanthine (mostly higher hypoxanthine results, but with some variable results in the
acute myocardial infarction samples). However, it is important to note that the hospital
patient samples may also have medications which contribute to the observed phenomena.
Based on these studies, it should be recommended that plasma (lithium heparin) be
used as the sample collection matrix for the analysis of human hypoxanthine and inosine.
While serum (without gel) appears to be an acceptable matrix, it does require waiting for
30 min for the blood to clot prior to centrifugation, thereby adding to the total time from
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patient sampling to analytical results to be returned from the clinical laboratory to the
emergency room physician.
The HPLC results from blood samples collected using different vacuutainer
additives (e.g. lithium heparin, SST) may help to explain differences in hypoxanthine
concentrations from the Kock et al. study (1994 article) and this research work. Kock et al.
reported no significant differences in hypoxanthine concentrations from their study
patients (e.g. acute MI patients versus healthy controls), whereas this research reports
significant differences from ED non-traumatic chest pain patients versus healthy normal
individuals. Two possible reasons may account for the reported differences in
hypoxanthine concentrations.
Firstly, the Koch et al. group used SST collection tubes and this study used lithium
heparin for collecting plasma; thus the blood collection additives were different. Secondly,
Koch et al. did not use ED non-traumatic chest pain patients (non acute MI when the blood
sample was drawn) for their study as were used in this research work. Since there are no
published kinetic studies of hypoxanthine in blood from non-traumatic chest pain or acute
myocardial infarction patients, it is possible that the concentrations of hypoxanthine in the
blood may be very different in these two groups of cardiac patients (e.g. patient chest pain
is a typical symptomatic event preceding an acute myocardial infarction).
When collecting blood from an individual, the choice of blood collection additives
can be just as important as the analytical test method. For this research, the differences
between collecting plasma (lithium heparin) and SST from whole blood demonstrated
variable hypoxanthine concentrations (artifacts). For example, in Figure 17, a consistent
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positive bias in hypoxanthine concentrations from SST samples relative to lithium heparin
plasma samples from normal healthy individuals (called matched sets) was demonstrated.
However variable hypoxanthine concentrations were observed in patients with heart
disease conditions (e.g. PromedDx lithium heparin plasma and SST matched set samples
representing hypertension (HT) and acute myocardial infarction (cTnI) patients are listed
in Appendix D), which indicates that hypoxanthine concentration artifacts may occur if
using SST collection tubes for hypoxanthine analysis.
Thus, in order to obtain reproducible inter-laboratory hypoxanthine concentration
results, lithium heparin should be used as the additive and not serum (SST), as the SST gel
appears to cause spurious artifacts. Artifacts using SST gels are not unique, as several
other investigators have reported similar findings when using serum (SST) for their studies
(e.g. progesterone, (Ferry et al., 1999); free triiodothyronine (FT3), Kilinc et al., 2002).
4.6

Conclusion
A sensitive and selective method has been developed for evaluation of inosine and

hypoxanthine in human plasma. The method employed a one step sample preparation for
plasma (no organic solvents or solid phase extraction cartridges required) with high analyte
recoveries, which eliminated the need for an internal standard. In addition, this method
utilized recently introduced HPLC monolithic column technology, which provided
sufficient selectivity and sensitivity for measurement of these components. Subject
matched set sample evaluation indicated a consistent positive bias in hypoxanthine levels
from use of SST collection tubes relative to plasma (heparin), thus the recommendation of
using plasma (heparin) collection to eliminate any potential artifacts and reduce total
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analysis time (serum and SST samples require ~30 min clotting time prior to
centrifugation). The method was employed without significant methodological problems
in the evaluation of plasma samples obtained from healthy individuals and hospital
emergency department patients presenting with non-traumatic chest pain with significant
levels of both inosine and hypoxanthine effluxed from the patient samples. These results,
albeit from a small sample size (n=20 each group), further support the research hypothesis
that these components may qualify as potential candidate biomarkers of acute cardiac
ischemia.
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CHAPTER 5. Rapid Chemiluminescence Detection of Inosine and
Hypoxanthine using Microplate Luminometer

5.1

Introduction
The goal of this chapter of research is the development of a rapid chemi-

luminescence test method for determination of inosine and hypoxanthine in human plasma.
The purpose is to allow for rapid patient screening capability (diagnostic tool for acute
cardiac ischemia) for potential use in hospital emergency department environments. The
luminescence method will be utilized on samples from healthy individuals and hospital
patients with confirmed acute MI (hospital documented elevated levels of cTnT). To be
effective, the method will need to be rapid (defined as less than 10 min analysis time),
sensitive and specific for inosine and hypoxanthine to reduce the potential errors in
interpreting sample test results (e.g. goal is to minimize false positive and false negative
results).
Currently, there are no published articles or U.S. patents for a rapid test method to
determine inosine and hypoxanthine in plasma, which can meet the stringent sample
turnaround time requirements of an emergency medical services (EMS) environment. The
rationale for using chemiluminescence technology over commonly used LC and
immunoassay technologies are as follows: LC and immunoassay methods are both very
sensitive and specific techniques (e.g. monoclonal antibodies for immunoassay and mass
spectrometer detection for LC); however, an LC-MS system is expensive to purchase and
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operate, both techniques require technical expertise to perform, and both lack a rapid
enough turnaround time needed by an EMS facility analyzing a priority “stat” type sample.
However, a luminometer can measure chemiluminescent light, is relatively inexpensive to
purchase, currently used in clinical labs (microplate capability), and can provide high
component sensitivity.
Luminescence technology is well established with many instrument vendors (e.g.
BMG LabTech Inc. Lumistar Optima (Durham, NC, USA), BioTek Synergy HT
(Winooski, Vermont, USA), Thermo Fisher Scientific Luminoskan (Waltham, MA, USA))
and suppliers (e.g. Corning Life Sciences, Lowell, MA, USA) of luminescence supplies
and reagents available worldwide. It is known to be one of the most sensitive techniques,
with one recent publication on its application for low ng/ml concentrations of ATP in
human plasma [Gorman et al., 2007]. The high sensitivity of luminescence is primarily
due to its high analyte signal to noise (s/n) ratio, with reported detection levels at low
picogram and femtogram levels.
To address biomarker specificity requirement, the developed luminescence test
method will utilize biological enzymes purine nucleoside phosphorylase (PNP) and
xanthine oxidase (XO), which are specific for enzymatic conversions of inosine and
hypoxanthine, respectively. The PNP enzyme converts inosine to hypoxanthine and XO
converts hypoxanthine to xanthine, followed by XO conversion of xanthine to final
product uric acid (in human species). Each time XO reacts with one mole of
hypoxanthine, and subsequently with one mole of xanthine, the metabolic by-products of
each XO enzymatic turnover is the production of one mole of hydrogen peroxide and two
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moles of superoxide anion radical (O2-·), which both of these by-products can become
substrates for luminescence type reactions. Several commonly used luminescent materials
(e.g. luminol (oxidation), lucigenin (reduction), and pholasin (oxidation)) were considered
for this research. If using luminol or lucigenin as the luminescent material, the hydrogen
peroxide (which has both oxidizing and reducing capabilities) can react with the
horseradish peroxidase (HRP) enzyme, luminol, and signal enhancers to generate
measurable blue light ~ 450 nm, thus an amplification of signal effect (one mole of
hypoxanthine and xanthine can generate two moles of hydrogen peroxide) (Figure 18).
However, to achieve even greater sensitivity as low concentration (ng/ml or µM)
levels of inosine and hypoxanthine are typically found in human plasma, another
luminescence approach was investigated, which utilizes a highly sensitive photoprotein
(pholasin®). Since one mole of hypoxanthine will generate 4 moles of superoxide anion
radicals (SAR) as a by-product of XO activity, using a chemiluminescent material that
reacts with SAR should theoretically provide even more luminescence signal, thus
potentially increasing the sensitivity twice fold over using the hydrogen
peroxide/horseradish peroxidase/luminol approach. One article cited pholasin having more
than 100 fold sensitivity than lucigenin (Knight, 1997).
Pholasin®, a photoprotein isolated from the bi-valve mollusk, has been reported to
be a very sensitive chemiluminescent material (called lucidalin®) for SAR and other
reactive oxygen species (ROS) such as the hydroxyl free radical (Knight, 1988). Pholasin®
has been extensively studied and patented by Knight Scientific, Plymouth, UK. It is an
approximately 34-36 kDa glycoprotein, which can be made excitable by several ROS,
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Figure 18. Diagram of enzymatic conversions of inosine and hypoxanthine components
with generation of hydrogen peroxide as a by-product, which can react with luminol or
lucigenin and HRP to generate visible blue light (chemiluminescence).
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emitting blue-green light, and it has been reported to not have fluorescent properties. The
presence of SAR can react with the pholasin photoprotein to generate measurable light
(~490 nm) (Figure 20), thus an amplification of signal effect (one mole of hypoxanthine
can generate four moles of SAR), which should increase sensitivity and provide lower
component detection limits. The reaction of pholasin with SAR can be very quick (flash
type technique, typically seconds) and may be made even more sensitive with use of signal
enhancers (e.g. Adjuvant-k (proprietary) from Knight Scientific).
The Lumistar Optima Microplate Reader (BMG LabTech, Durham, NC, USA) was
used for all luminescence evaluations. The instrument has temperature control, supports
the use of 96 well plates (opaque white) which were purchased from Corning Life Sciences
(Lowell, MA, USA), and is capable of variable microplate mixing speeds with flash and
glow luminescence capabilities. The instrument is fitted with two direct injectors capable
of rapid injections (e.g. 310 ul/sec), thus micropipetting assay reagents into the sample
wells was automatically performed, which may help to reduce potential errors from manual
pipetting.
5.2

Experimental

5.2.1

Chemicals, Reagents and Materials
Hypoxanthine, xanthine and ethyl alcohol (HPLC grade, denatured) were

purchased from Acros Organics (Fair Lawn, NJ, USA). Inosine, dibasic sodium hydrogen
phosphate, and uric acid were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Enzymes xanthine oxidase (isolated from bovine milk, Grade III, ammonium sulfate
suspension, enzymatic activity ~1.3 units/mg protein, storage temp 2-8°C),
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purine nucleoside phosphorylase (isolated from human blood, lyophilized powder,
enzymatic activity ~19 units/mg protein., storage -20°C) and uricase (isolated from
Arthrobacter globiformis, lyophilized powder, ~19.7 units/mg protein, storage -20°C) were
all purchased from Sigma-Aldrich.
A commercial test kit used for antioxidant evaluations was purchased for initial
setup of the luminometer and included an assay utilizing xanthine/xanthine oxidase plate
mode kinetics (glow technique). The kit included pholasin (50 µg), xanthine, xanthine
oxidase [~10.25 mU/ml] and buffer (proprietary) for plate mode kinetics and was
purchased from Knight Scientific (Plymouth, UK). The luminometer instrument was
qualified using the commercial antioxidant test kit and by successful replication of the
xanthine/xanthine oxidase plate mode kinetics profile from Knight Scientific. For all
experiments following instrument qualification, the reagents and enzyme solutions were
prepared accordingly. Dibasic sodium hydrogen phosphate was used to prepare the 20
mM assay buffer solution with ultrapure deionized water as the diluent (final pH 7.4 using
concentrated phosphoric acid). Ultrapure deionized water (~18 MΩ-cm) used for all
reagent solutions was filtered (0.2 µm) prior to use.
The luminometer rinse solution for the direct injector syringes was prepared using
ethyl alcohol:deionized water mixture (75:25%, v/v). Weekly rinses were performed to
reduce potential material (e.g. protein and enzyme residue) buildup in the syringes, reagent
tubing and injector needles. Opaque 96 well microplates were purchased from Corning
Life Sciences (Lowell, MA, USA) and stored in the dark at ambient temperature. Blank
human plasma (lithium anticoagulant) from one healthy volunteer (250 ml), an additional
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six healthy volunteers plasma (lithium heparin) samples (1 ml each), and six patient’s
plasma (lithium heparin) samples with confirmed acute MI (hospital reported elevated
cTnT, 1 ml each) were purchased from ProMedDx (Norton, MA, USA) and stored at 20°C prior to use.
5.2.2

Preparation of Standards, Enzymes and Pholasin Solutions
Stock standards of inosine (25 µg/ml, 93.2 µM), hypoxanthine (25 µg/ml, 183.7

µM), xanthine (25 µg/ml, 164.4 µM) and uric acid (25 µg/ml, 148.7 µM) were prepared in
deionized water, stored at 4°C with stability greater than 3 months. Working calibration
standards for each component were prepared in deionized water immediately prior to use.
For experiments, the working xanthine oxidase solution was prepared by pipetting
40 µL of the aqueous stock XO (from bovine milk) suspension into 2.0 ml of assay buffer
(pH 7.4) resulting in ~676 mU XO/ml. The working XO solution was stable at ambient
laboratory temperature (22°C) and could be stored at 4°C overnight with minimal loss in
enzyme activity; however the working XO solution should not be stored frozen
(e.g. -20°C), as a complete loss of enzyme activity was observed upon freeze-thaw and
subsequent use.
To prepare PNP and uricase solutions from solid and lyophilized purine nucleoside
phosphorylase and uricase, 1.0 ml of assay buffer (pH 7.4) was pipetted directly into the
vendor container bottle with gentle vortexing into solution. After reconstitution using 1 ml
of assay buffer (pH 7.4), the PNP stock concentration was ~18.7 Units PNP/ml and uricase
stock concentration was ~110 Units uricase/ml. A working solution of PNP [~701 mU
PNP/ml] was prepared by pipetting 75 µL of the aqueous stock material into 2.0 ml of
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assay buffer (pH 7.4). A working solution of uricase [~1.1 U uricase/ml] was prepared by
pipetting 20 µL of the aqueous stock material into 2.0 ml of assay buffer (pH 7.4). Both
working solutions of PNP and uricase were stable at ambient laboratory temperature and
could be stored at 4°C overnight with minimal loss in enzyme activity.
For preparation of the pholasin luminescent material, 5.0 ml of assay buffer (pH
7.4) was pipetted directly into the vendor container bottle containing 50 µg pholasin with
gentle vortexing, resulting in a ~10 µg/ml solution. The prepared pholasin reagent was
stable at ambient laboratory temperature and 4°C, and was stored protected from light to
eliminate potential basal luminescence as it is an excitable photoprotein. The reconstituted
pholasin solution was transferred and stored in plastic screw top tubes (~1 ml aliquots
stored at -20°C).
5.2.3

Luminometer Equipment and Set Points
The luminometer equipment consisted of a BMG LabTech Inc. Lumistar Optima

and Optima software (version 2.1) (Durham, NC, USA) and Dell Optiplex 745 PC (Dell,
TX, USA). The luminometer was equipped with temperature control (8°C to 45°C), two
direct injectors (minimum injection volume of 3 µl) with variable injection speeds (100 µ/s
to 420 µ/s), and microplate shaking (orbital, linear, figure eight) capability. The
luminometer listed specifications for the limit of detection (<50 amol / well ATP), spectral
range (240 – 740 nm) and dynamic range (9 decades). All luminescence assays utilized
opaque 96 well plates, an incubation temperature of 25°C, lens mode (no emission filter)
and a photo-multiplier (PMT) gain setting of 3900 volts. Equipment set points for all
experiments in the flash mode are listed in Figure 21.
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Figure 21. BMG luminometer set points used for flash mode experiments.
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5.2.4

Method Development and Optimization
Development and optimization of the luminescence test method included

evaluation of parameters such as determining hypoxanthine concentration level range,
adjustment of XO enzyme concentration level to reduce analysis time, and enzyme
incubation time (e.g. PNP) to maximize sensitivity and repeatability and to minimize
turnaround time (<10 min analysis). All plasma analysis utilized 20 µl of sample in a final
microplate well volume of 200 µl (effectively making a 1:10 dilution of the plasma
sample). Potential endogenous interference (e.g. uric acid) was evaluated to determine
quenching effects as this substance has antioxidant capacity and is typically found in
plasma at high concentrations (e.g. 350-450 µM), especially in gout patients.
The HPLC results from normal volunteers (ProMedDx plasma) and non-traumatic
chest pain patients (Chippenham Hospital ED plasma) from Chapter 4 were used to
estimate expected plasma concentrations of inosine and hypoxanthine for this chapter of
research (Table 9). Since the luminometer is a detection device and will not separate a
mixture of components (as does HPLC), it was necessary to utilize the PNP enzyme and
convert component inosine to hypoxanthine, and then measure the resulting total plasma
hypoxanthine (inosine plus hypoxanthine) concentration. Using the XO enzyme,
hypoxanthine converts to xanthine, and xanthine to uric acid. The luminometer measures
the light signal generated from the XO reaction with hypoxanthine and xanthine (XO
generates superoxide anion radicals which react with the luminescent material pholasin).
Using a µg/ml to µM (micro molar) conversion table (Excel formula computations, Table
10), a standard curve of hypoxanthine was prepared at concentration range of
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Table 9. Estimated inosine, hypoxanthine, xanthine and uric acid concentrations in healthy
normal individuals and non-traumatic chest pain patients. Values for normal individuals
are based on published literature and the HPLC results using PromedDx healthy normal
individuals. Values for potential acute cardiac ischemia are from the HPLC results using
Chippenham Emergency Department plasma (heparin) samples.

Plasma Plasma
[ug/mL] [uM] Comments
Estimated lowest inosine level = 0.10
0.4
Estimated lowest hypoxanthine level = 0.10
0.7
Assume 100 %ino to hypo conv
hypo =
1.1 Estimated levels (normals), n=20 fromPromedDx
Estimated (normals) inosine level = 0.30
Estimated (normals) hypoxanthine level = 0.30
Assume 100 %ino to hypo conv
hypo =

1.1
2.2
3.3

Estimated (ischemic) inosine level = 0.3
Estimated (ischemic) hypoxanthine level = 2.0
Assume 100 %ino to hypo conv
hypo =

1.1 Lowest chest pain patient value
14.7
15.8 Ischemic (based on ChippenhamEDdata).

Estimated (ischemic) inosine level = 7.8
Estimated (ischemic) hypoxanthine level = 9.7
Assume 100 %ino to hypo conv
hypo =

29.1 Highest chest pain patient value
71.3
100.3 Ischemic (based on ChippenhamEDdata).

Estimated (normals) xanthine level =

0.9

Estimated (normals) uric acid level = 60.0
Estimated (normals, high) uric acid level = 80.0
Estimated uric acid highest level (gout) = 100.0

5.9

Estimated levels (normals) fromFeng et al, Ther Drug Mon (2000) 22:177-183.

Estimated xanthine levels (normals) fromFeng et al, Ther Drug Mon (2000) 22:177-183.

356.9 Potential XOinhibitor and luminescence quenching (anti-oxidant).
475.9 Potential XOinhibitor and luminescence quenching (anti-oxidant).
594.8 Potential XOinhibitor and luminescence quenching (anti-oxidant).
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Table 10. Component µg/ml to µM conversion table.
For Experiments
Compound
Adenosine
Inosine
Hypoxanthine
Xanthine
Uric Acid

Weight
mg
25.0
25.0
25.0
25.0
25.0

Volume
Ml
1000.0
1000.0
1000.0
1000.0
1000.0

Conc
µg/ml
25.0
25.0
25.0
25.0
25.0

Conc
µM
93.6
93.2
183.7
164.4
148.7
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2.3 to 30.3 µM. The initial hypoxanthine concentration range was set to focus on
hypoxanthine concentrations to maximize the luminescence method sensitivity and detect
concentration differences between healthy normal individuals and non-traumatic chest pain
patients (e.g. ~3 µM for normal individual and ~15 µM for lowest observed chest pain
patient). Plasma samples above the highest standard can be diluted with deionized water.
The initial range incorporated total inosine and hypoxanthine concentrations from both
healthy normal individuals and non-traumatic chest pain patients (based on n=20 for each
group from Chapter 4 research). However it is important to note that this small set of
plasma samples may not cover the entire range of hypoxanthine concentrations from a
larger patient population, and further research work is necessary to optimize the
hypoxanthine standard curve, as the goal of this chapter of research is the development of a
rapid and simple method.
Xanthine was found to be at a constant concentration (~6 µM) in both normal
individuals and non-traumatic chest pain patient samples. It is important to discuss why a
standard curve of xanthine would not be used for this assay. To prepare a standard curve
of xanthine for computation of inosine and hypoxanthine concentrations would report
erroneously low results, as xanthine only activates the XO enzyme once (xanthine to uric
acid), whereas hypoxanthine activates the XO enzyme twice (hypoxanthine to xanthine to
uric acid). Since we are only interested in inosine and hypoxanthine concentrations for this
research, and with xanthine levels constant, it was appropriate to prepare hypoxanthine
standards (which incorporated total inosine to hypoxanthine conversion) for this research
project.
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Typical spreadsheets used for luminescence experiments on inosine, xanthine, and
hypoxanthine evaluations include each reagent preparation, volume pipetted into the well,
and target concentrations and are listed in Tables 11, 12, and 13, respectively. Using the
experimental spreadsheet for each component standard concentration range, plasma (20 µl)
was pipetted into the microplate well with reagents (e.g. assay buffer, phosalin, PNP,
uricase) either manually pipetted or injected using one direct injector; with the other direct
injector used to inject the XO solution to start the reaction with pholasin and subsequent
luminescence emission.
5.2.5

Luminescence Computations
All computations were performed using BMG Excel software (with built in

macros) and data processing set points as defined by the method. Figure 22 and 23
represents a scan (plasma with 10 µM hypoxanthine) and the RLU tabulated results (e.g.
BMG Excel Table 1, 2, and 3 in Figure 23) from raw data acquired over the analytical run
and with data acquisition set at one data point per second. The background (baseline)
luminescence signal (labeled as Range 1 and presented in BMG Excel Table 1) can be
caused by reagents (e.g. buffer, pholasin, PNP, plasma) and electronic noise and was
calculated as the maximum RLU signal between scan times 100-118 seconds. It would
have been more appropriate to average the background RLU signal; however the BMG
Excel software was written to have the same computation applied to both table ranges and
does not currently allow the flexibility of independent computations on each individual
table.
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Table 11. Typical spreadsheet used for inosine luminescence experiments.
Total
well
volu
me

Final Inosine Conc.
(200 ul well volume)

Inosine

Standard Inosine

Pholasin

Assay
buffer

PNP

XO

[uM]

(ul)

WS [uM]

(ul)

(ul)

(ul)

(ul)

(ul)

0.0

0

0

50

70.0

40

40

200

1.0

21.5

9.32

50

48.5

40

40

200

2.5

53.6

9.32

50

16.4

40

40

200

5.0

10.7

93.2

50

59.3

40

40

200

10.0

21.5

93.2

50

48.5

40

40

200

20.0

42.9

93.2

50

27.1

40

40

200

30.0

64.4

93.2

50

5.6

40

40

200

Example

Plasma (ul)
0

50

50.0

40

40

200

If plasma sample 1:10 dilution

20

Notes:
1. Stock inosine [93.2 uM or 25 ug/ml] in DI. Prepared by adding 25 mg in 1000 mL DI (or assay buffer).
2. Working stock (WS)

WS-1 (9.32 uM)

100 ul stock inosine

(1:10 stock)

900 ul assay buffer

3. Final total inosine conc based on 200 ul well volume.

4. Pholasin conc [10 ug/ml].

Add 5 ml assay buffer to vial (50 ug pholasin from mollusca, Knight Scientific). Store
frozen.

5. XO conc [~676 mU XO /
ml].

Pipet 40 ul stock (XO from bovine milk, Sigma) to 2 ml assay buffer. Store
refrigerated.

6. PNP conc [~701 mU PNP /
ml].

Pipet 75 ul stock (PNP from human RBC, Sigma) to 2 ml assay buffer. Store
refrigerated.
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Table 12. Typical spreadsheet used for xanthine luminescence experiments.

Final Xanthine Conc.
(200 ul well volume)
[uM]
0.0
1.0
2.5
5.0
10.0
20.0
30.0
Example
If plasma sample 1:10 dilution

Xanthine
(ul)
0
12.2
30.5
61.0
12.2
24.3
36.5

Standard
Xanthine
WS [uM]
0
16.4
16.4
16.4
164.4
164.4
164.4

Pholasin
(ul)
50
50
50
50
50
50
50

Assay buffer
(ul)
110.0
97.8
79.5
49.0
97.8
85.7
73.5

XO
(ul)
40
40
40
40
40
40
40

Total
well
volume
(ul)
200
200
200
200
200
200
200

Plasma (ul)
20

0

50

90

40

200

Notes:
1. Stock xanthine [164.4 uM or 25 ug/ml] in DI. Prepared by adding 25 mg in 1000 mL DI (or assay buffer).

2. Working stock (WS)

WS-1 (16.4
uM)
(1:10 stock)

100 ul stock xanthine
900 ul assay buffer

3. Final xanthine conc based on 200 ul total well volume.

4. Pholasin conc [10 ug/ml].

Add 5 ml assay buffer to vial (50 ug pholasin from mollusca, Knight Scientific). Store
frozen.

5. XO conc [~676 mU XO / ml].

Pipet 40 ul stock (XO from bovine milk, Sigma) to 2 ml assay buffer. Store
refrigerated.
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Table 13. Typical spreadsheet used for hypoxanthine luminescence experiments.
Final Hypoxanthine
Conc.
(200 ul well volume)

Total
well
volume

Assay
buffer

XO

(ul)

(ul)

(ul)

(ul)

50

110.0

40

200

1.84

50

99.1

40

200

1.84

50

88.2

40

200

54.4

1.84

50

55.6

40

200

1.0

10.9

18.37

50

99.1

40

200

2.0

21.8

18.37

50

88.2

40

200

5.0

5.4

183.7

50

104.6

40

200

10.0

10.9

183.7

50

99.1

40

200

0

50

90

40

200

Hypoxanthine

Standard
Hypoxanthine

Pholasin

[uM]

(ul)

WS [uM]

0.0

0

0

0.1

10.9

0.2

21.8

0.5

Example
If plasma sample 1:10
dilution

Plasma (ul)
20

Notes:
1. Stock hypoxanthine [183.7 uM or 25 ug/ml] in DI. Prepared by adding 25 mg in 1000 mL DI (or assay
buffer).
2. Working stock (WS)

WS-1 (18.37 uM)
(1:10 stock)
WS-2 (1.84 uM)
(1:10 WS-1)

100 ul stock hypoxanthine
900 ul assay buffer
100 ul WS-1 hypoxanthine
900 ul assay buffer

3. Final total hypoxanthine conc based on 200 ul well
volume.
4. Pholasin conc [10
ug/ml].

Add 5 ml assay buffer to vial (50 ug pholasin from mollusca, Knight Scientific). Store frozen.

5. XO conc [~676 mU XO /
ml].

Pipet 40 ul stock (XO from bovine milk, Sigma) to 2 ml assay buffer. Store refrigerated.

6. Target range of nucleoside/purine assay (includes xanthine plus ino and hypo conversion to xanthine) is ~2 uM (normals)
up to ~100 uM (ischemic).
7. Sensitivity and linearity of the nucleoside/purine assay (if 1:10 dilution of plasma) needs to be ~0.1 up to ~10 uM.
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Figure 22. Typical BMG output luminescence scan for sample analysis of 10 µM
hypoxanthine in plasma. Range one (background RLU measurement between 100 and 120
sec) and range two (peak height RLU measurement between 120 sec and 222 sec).
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Figure 23. BMG Excel computations, method and data processing set points, and file
name are documented for GLP compliance. Results are reported in excel cells based on
microplate sample well location (96 well plates).
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The peak luminescence signal from the generation of light from pholasin (labeled
as Range 2 and presented in BMG Excel Table 2) and superoxide anion radicals was
calculated as the maximum RLU peak height signal between scan times 119-222 seconds.
BMG Excel Table 3 represents the net RLU and is calculated by subtracting the
background signal (BMG Excel Table 1) from the peak luminescent signal (BMG Excel
Table 2). The use of the peak height response of the RLU was used for the computations
on these plasma samples, as some patient plasma samples RLU responses were very slow
to return to background (baseline) RLU levels. The cause of the slow RLU signal return to
baseline is unknown, but may be due to patient medications (e.g. vasodilators, salicylic
acid) used for treatment of acute MI patients.
As this luminescence method was set up for rapid screening purposes on potential
non-traumatic chest pain patient samples from the ED, it was not developed to be a
quantitative assay as was the validated HPLC-UV method (Chapter 4). However, the
luminescence method needed to be rapid (<10 min analysis), sensitive (use 20 ul plasma),
specific (use of enzymes) and have high precision (repeatability) to be useful in the ED
environment. This luminescence method was developed to compare the RLU differences
between healthy normal individual plasma samples (negative control) and samples from
ED non-traumatic chest pain patients that may be experiencing acute cardiac ischemia.
A comparison was made of the net RLU value between the non-traumatic chest
pain patient and negative control sample, using a calculated 99% RLU reference cut-off
value generated from healthy normal individuals, as the decision making RLU cut-off
level. Determining the 99% RLU cut-off value (which is beyond the scope of this

146
research) would best be determined using a large number of healthy normal individuals
(e.g. >>100)) and calculated using the RLU mean value plus the 2.326 standard deviations
(α=0.01, one tail, 99% confidence interval), and would be used to determine whether the
patient has acute cardiac ischemia causing the reported chest pain.
For example, if a non-traumatic chest pain patient net RLU was similar to a
negative control sample net RLU, then the patient was most likely not having an acute
cardiac ischemic event, but had some other type of medical condition (e.g. anxiety,
heartburn) causing the reported chest pain. However, if a patient’s net RLU was above the
99% RLU reference cut-off value for healthy normal individuals, then the patient was
probably experiencing an acute cardiac ischemic event, and would require immediate
medical attention, as it may lead to acute MI and potential adverse outcome.
5.3

Results and Discussion
To setup the new luminometer equipment, a standardized plate mode luminescence

test kit was bought (ABEL 61M Antioxidant Test Kit, Knight Scientific, Ltd) which
evaluates antioxidant capability using xanthine/xanthine oxidase and pholasin. This test
kit was used to qualify the new luminometer equipment using a standardized plate mode
(glow technique). However, method modifications were necessary as the plate mode
analysis run time was approximately 30 min and had low sensitivity (Figure 24) as it is
developed primarily for antioxidant and glow kinetic type studies, which would be
insufficient for our research objective of a rapid and sensitive assay.
Adjustments were made to the level of XO used for analysis to increase the
reaction rate (flash mode) and the incubation time of PNP enzyme for plasma inosine
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Plate Mode Kinetics
30 µM Xanthine in Assay Buffer
50000
40000
RLU 30000

30 µM Xanthine

20000

30 µM Xanthine

10000
0
0

500

1000

1500

2000

Time (sec)

Figure 24. Chart of relative light units (RLU) versus time (sec) for 30 µM xanthine/XO
plate mode kinetics. The profile demonstrates successful new equipment setup and
operation using a commercial test kit for antioxidant evaluation (ABEL 61-M, Knight
Scientific). Two individual samples overlay with analysis time ~30 min.
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conversion to hypoxanthine. The starting level of XO enzyme level for the plate mode was
approximately 10.25 mU/ml after reconstitution with assay buffer. With adjustment of XO
to increase the concentration, the final working concentration was approximately 676
mU/ml. This resulted in an analysis time reduction from approximately 30 min to 5 min
(Figure 25). Since the commercial kit from Knight Scientific (plate mode) was set up for
xanthine/xanthine oxidase analysis and studies on material antioxidant capabilities, it was
necessary to increase the XO level to additionally incorporate plasma hypoxanthine levels,
but more importantly to reduce the time of analysis to under 10 min (i.e. switch from glow
mode to flash mode kinetics).
A standard curve of hypoxanthine was evaluated at concentrations from 2.3 to 30.3
µM and demonstrated sufficient linearity (normal linear regression) with correlation
coefficient >0.9990 (n=2). The incubation time of purine nucleoside phosphorylase was
evaluated at 60 and 120 second equilibration times using 10 μM inosine as the substrate
with the monitoring of hypoxanthine level (Figure 26). Therefore, the PNP incubation
time should remain set at 120 sec to allow for complete inosine to hypoxanthine
conversion, with subsequent XO injection to start the luminescence reaction. For future
work, one possible way to reduce the overall analysis time would be to add the PNP
enzyme to the sample collection tube (e.g. BD vacuutainer), with inosine conversion then
occurring during the whole blood to plasma centrifugation step. If this centrifugation
technique utilizing PNP in the vacuutainer results in complete inosine to hypoxanthine
conversion, it would eliminate the need for the 120 sec PNP incubation time; and reduce
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VCU Blood Bank Plasma (Acid Citrate)
Basal vs 2µM vs10 µM Hypo
12000

VCU Blood Bank

10000
8000
RLU

VCU with 2 µM
hypo

6000
4000

VCU with 10 µM
hypo

2000
0
0

100

200

Time (sec)

Figure 25. Chart demonstrating a significantly reduced analysis time by utilizing increased
amounts of XO (from ~10.3 mU/ml to ~676 mU/ml) and continuous microplate mixing.
Analysis time ~3.7 min.
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10 uM Ino in Assay Buffer
1,000,000

RLU

800,000

Injector time study (60
sec)

600,000

Injector time study (120
sec)

400,000
200,000
0
0

50

100

150

200

Time (sec)

ProMedDX 10372027 Plasma (Heparin)
10 µM Ino/PNP versus 10 µM Hypo Std

16000
14000
12000
10000
RLU
8000
6000
4000
2000
0

Promed 10372027
c 10 µM Ino
Promed 10372027
c 10 µM Ino
Promed 10372027
with 10 µM hypo

0

50

100

150

200

Time (sec)
Figure 26. Charts depicting inosine and PNP incubation time and conversion study.
Evaluation of 60 and 120 sec PNP incubation times, with 120 sec demonstrating the
complete conversion of inosine to hypoxanthine. The 10 µM inosine with PNP conversion
RLU responses (n=2) overlays completely against the 10 µM hypoxanthine standard.
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the analysis time to only 30 seconds (assumes injection of XO at 0.1 sec and measurement
of peak height RLU response).
A study of the effect of plasma uric acid on luminescence response was performed.
Since uric acid is found in plasma at relatively higher concentrations (normal range ~350475 µM) and is a known antioxidant, it was important to evaluate its potential effect on the
luminescence signal. As seen in Figure 27, the uric acid’s antioxidant affects decreases the
luminescence signal (~50% quenching). To address the uric acid, an experiment was
performed using strong anion exchange (SAX) resin to remove organic anions from the
plasma matrix. Also seen in Figure 27 is a 1:100 dilution of plasma and subsequent use of
the SAX pipet tip (Varian, Inc, CA, USA); both demonstrated that removal of potential
interfering organic acids (e.g. urate at pH 7.4) resulted with an increase in luminescence
response and sensitivity. Since the blank plasma used had approximately 500 nM
hypoxanthine, the 1:100 dilution using deionized water and subsequent use of SAX sorbent
makes detection levels of hypoxanthine at the pM levels attainable.
A second approach to eliminate the uric acid was to utilize uricase (~1.1 U/ml from
Arthrobacter globiformis bacteria, Sigma, USA) during the PNP incubation time in an
attempt to eliminate the endogenous uric acid. As seen in Figure 28, it appears that the XO
enzyme is deactivated (product inhibition) by the presence of large amounts of by-product
hydrogen peroxide that is generated by uricase activity. As one by-product of XO activity
is the production of hydrogen peroxide, this finding was not completely surprising due to
the effects of product inhibition on XO enzyme turnover. One possible solution to
eliminate the generated hydrogen peroxide is to use horseradish peroxidase, which
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10 uM Hypo with UA in Assay Buffer
1,000,000

RLU

800,000
74.4 uM UA (gout)

600,000

37.2 uM UA (normals)

400,000

10 uM Hypo

200,000
0
0

50

100

150

200

Time (sec)

ProMedDX 11136468 Plasma (Heparin)
Normals (no dilution vs 1:100 vs 1:100 with SAX)
12000

Promed Blk
11136468

10000
RLU

8000

1:100 dil

6000
4000

1:100 dil and SAX

2000
0
0

50

100

150

200

Time (sec)

Figure 27. Charts demonstrating effects of uric acid (human physiological levels) on
pholasin luminescence signal. High levels of uric acid (in buffer) can quench the
luminescence by more than 50%. Treatment of plasma (1:100 dilution) and use of strong
anion exchange (SAX) can reduce antioxidant effect on the luminescence signal and
increase method sensitivity.
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ProMedDx #10372026 Plasma (Heparin)
Basal vs 10 µM Hypo with Uricase
120000

Blk plasma with uricase

100000

Blk plasma with uricase

RLU

80000
60000

Blk plasma with uricase (10 µM
hypo)
Blk plasma with uricase (10 µM
hypo)

40000
20000
0
0.00

50.00

100.00 150.00 200.00
Time (sec)

Figure 28. Chart demonstrating the effect of uricase on basal uric acid levels (normal
healthy individual) and with fortification of 10 µM hypoxanthine. The generation of
hydrogen peroxide (by-product) from uricase enzymatic conversion of uric acid to
allantoin caused XO inactivity (potentially from hydrogen peroxide product inhibition on
XO effect).
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catalyzes hydrogen peroxide to products water and oxygen, but this additional enzyme
would only add to the complexity and cost of the analysis and therefore not evaluated.
However, the use of the both uricase and SAX pipet tip technology to eliminate
organic acids (e.g. uric acid) was probably not necessary to use, as differences in
luminescence response between the healthy normal individuals and confirmed acute MI
patients (elevated cTnT levels) was significant (t-test, α=0.05, p<0.01), when using the
99% percentile (α=0.01, one tail, 2.326 standard deviations for n=6) as the calculated
biomarker cut-off reference value for acute cardiac ischemia (Figure 29). Even though this
research utilized a small sample set for evaluation (n=6 for each group), the 99% cut-off
for healthy normal individuals was 5,946 RLU, with all six cTnT patients clearly above
this calculated decision point cut-off RLU level. The luminescence method was optimized
for rapid evaluation of hypoxanthine in plasma to potentially be used in an ED clinical type
environment. For this research study, method parameters such as calibration, repeatability
and limit of detection were evaluated using hypoxanthine standards.
The method demonstrated linearity from 2.3-30.3 µM hypoxanthine in assay buffer
(R=0.9990, n=2) (Figure 30). This range covered the low and midpoint total hypoxanthine
concentrations of samples from HPLC analysis of healthy individuals and non-traumatic
chest pain patients (Figure 16), and focused on the potential biomarker cut-off
concentration for this small group of samples (n=20). Repeatability (n=3) was evaluated
by fortification of plasma at basal (~0.5 µM) and 1.5 µM hypoxanthine concentrations
(final well levels) and demonstrated by consistent RLU overlays (Figure 31).
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ProMedDx Plasma (Heparin)
Normals basal total ino/hypo (n=6)

#2558 Normal; hypo 351
ng/mL
#2559 Normal; hypo 389
ng/mL

45000
40000
35000
30000
RLU 25000
20000
15000
10000
5000
0

#7652 Normal; hypo 407
ng/mL
#7653 Normal; hypo 339
ng/mL
#7654 Normal; hypo 208
ng/mL

0

100
Time (sec)

200

ProMedDx Plasma (Heparin)
cTnT Patients (acute MI) & total ino/hypo (n=6)

#7655 Normal; hypo 309
ng/mL

#7150 cTnT 0.54 ug/L;
hypo 3,422 ng/mL
#7157 cTnT 0.62 ug/L;
hypo 1,866 ng/mL

45000
40000
35000
30000
RLU 25000
20000
15000
10000
5000
0

#7158 cTnT 0.69 ug/L;
hypo 1,208 ng/mL
#6441 cTnT 0.53 ug/L;
hypo 8,459 ng/mL
#6442 cTnT 0.60 ug/L;
hypo 4,019 ng/mL

0

100
Time (sec)

200

#6738 cTnT 0.60 ug/L;
hypo 4,533 ng/mL

Figure 29. Charts demonstrating healthy normal individuals and patients with confirmed
acute MI (hospital documented elevated levels of cTnT). All cTnT patient samples RLU
response were clearly above the calculated 99% cut-off reference value (5,944 RLU) for
healthy normal individuals (n=6 for each group). HPLC values for total hypoxanthine
(from Chapter 4) and cTnT values (from ProMedDx) are listed in the legend.
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Hypoxanthine Standard Curve
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Figure 30. Hypoxanthine standard curve in assay buffer ranging from 2.3 to 30.3 µM
demonstrating sufficient linearity and back-calculated hypoxanthine concentrations.
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Figure 31. Charts demonstrating repeatability of the luminescence assay. Healthy normal
individual (basal level, ~0.5 µM hypoxanthine) and fortified sample (1.5 µM
hypoxanthine) assayed three consecutive times. Overlay of profiles demonstrate plasma
sample repeatability.

158
5.4

Conclusion
A rapid luminescence method was developed for the detection of inosine and

hypoxanthine in human plasma. Using only 20 ul of plasma (heparin) and instrument
direct injectors, the method allowed for the rapid (<5 min) detection of total hypoxanthine
(as inosine is converted to hypoxanthine using enzyme PNP) concentrations, which may
potentially be used as a biomarker of acute cardiac ischemia. The use of a hypothetical
cut-off level (e.g. 99% confidence) relative luminescence unit (RLU) for decision making
(i.e. positive level, negative level) may be the most effective use of this rapid screening
assay. The method was utilized for evaluation of plasma samples from healthy individuals
and cardiac patients with confirmed acute myocardial infarction (hospital documented
elevated plasma cTnT levels), and demonstrated the potential of this rapid assay to be used
as a diagnostic tool, for use by emergency department services personnel on non-traumatic
chest pain patients suspected of undergoing acute cardiac ischemia.
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CHAPTER 6. Summary Research Conclusions and Potential Limitations

With cardiovascular disease (e.g. acute myocardial infarction (MI)) being one of
the leading causes of mortality in the world, a rapid patient assessment, diagnosis and
treatment is important to improving patient outcomes. This research investigation focused
on the use of endogenous plasma levels of inosine (hypoxanthine precursor) and
hypoxanthine, as a potential diagnostic tool for use in the evaluation of emergency
department non-traumatic chest pain patients. The research was divided into three phases
with highlighted research goals as follows: Phase I. Animal (mouse) experiments to
identify potential biomarker(s) and demonstrate biomarker proof-of-concept and disease
condition (acute cardiac ischemia); Phase II. Evaluation of healthy normal individuals and
ED non-traumatic chest pain patients plasma samples for the identified biomarker(s) from
Phase I studies; Phase III. Development of a sensitive and rapid clinical assay (<10 min
analysis goal) for detection of inosine and hypoxanthine in human plasma.
Phase I research utilized the ICR mouse model for all experiments. Briefly, the
mice were anaesthetized; hearts removed and isolated onto a Langendorff apparatus, with
Krebs buffer solution providing physiological nutrients. For ischemic conditions, the
isolated heart experiments consisted of 30 min stabilization, 20 min zero-flow global
ischemia, followed by 30 min of Krebs buffer reperfusion. Time-matched studies were
carried out for control (non-ischemic) and test (ischemic) experimental groups. Upon heart
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reperfusion, approximately 1.5 ml samples of the Krebs buffered perfusate from isolated
mouse hearts were collected at time-points (0, 1, 3, 5, 10 and 20 min) and stored frozen (20°C) until analysis. An HPLC-UV method was developed and validated for sample
analysis with LC-MS used for biomarker identification. Results from this phase of
research demonstrated the significant increase in levels of inosine (t-test, p<0.05) and
elevated levels of hypoxanthine from isolated mouse hearts undergoing 20 min acute
global ischemia relative to the non-ischemia control group.
An evaluation of the effects of salicylic acid (SA) in Krebs buffer solution was
made, as aspirin (ASA, salicylic acid precursor) is used as part of the initial treatment for
patients suspected of undergoing acute MI, to reduce platelet formation at the site of the
thrombus (clot). Results of mouse hearts undergoing 20 min acute global ischemia and
exposure to 0.1 and 1.0 mM SA concentrations both demonstrated a potentiation of
effluxed inosine from the affected heart tissue. As any further work using SA was beyond
the scope of this research project, however it is strongly recommended that additional
research using animal models are performed on the apparent adverse effects of ASA and
SA on ATP catabolism under conditions of acute cardiac ischemia. Knowing how
widespread ASA is used for other medical treatments (e.g. analgesia, rheumatoid arthritis)
and the possibility of those patients one day experiencing an acute cardiac ischemic event,
supports the recommendation of further research on aspirin and its metabolite, salicylic
acid on ATP catabolism.
Phase II research evaluated plasma samples representing healthy normal
individuals and local hospital emergency department non-traumatic chest pain patients.
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Samples were evaluated using a modified and validated HPLC-UV method from Phase I
studies. An evaluation of sample collection (matched subject sets of plasma (heparin) and
serum separator tube (SST) samples) was performed to determine if inosine and
hypoxanthine component differences exist between these two frequently used blood
collection techniques. Results of this phase of research demonstrated elevated amounts of
hypoxanthine concentrations (~19% positive bias) from blood samples collected using SST
tubes, relative to the collection of plasma (heparin). The use of the anticoagulant heparin
for obtaining blood samples for these test procedures is recommended; as it eliminates the
potential positive bias in hypoxanthine concentrations, and it ultimately saves time (SST
requires a recommended clotting time of 30 min prior to the centrifugation step).
Significant differences (t-test, p<0.05) were found for plasma concentrations of inosine and
hypoxanthine detected from emergency department patients presenting with non-traumatic
chest pain relative to healthy normal individuals.
Phase III research focused on the initial development of a rapid (<10 min analysis
goal) luminescence assay for plasma inosine and hypoxanthine, to potentially be used in
hospital clinical laboratory or point-of-care environments. Briefly, the assay utilized 20 ul
plasma with enzymes purine nucleoside phosphorylase (PNP) used for conversion of
plasma inosine to hypoxanthine, and xanthine oxidase (XO) used for conversion of
hypoxanthine to xanthine, and xanthine to uric acid. One metabolic by-product of the XO
enzymatic conversion is the generation of highly reactive superoxide anion radicals, which
can react with pholasin® (a photoprotein) to generate blue-green light measurable using a
luminometer.
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The luminescence assay was utilized for rapid detection of plasma concentrations
of inosine and hypoxanthine obtained from healthy normal individuals and hospital acute
MI patients (hospital documented elevated cTnT plasma levels). Using a calculated 99th
RLU (relative luminescence unit) percentile reference cut-off level from the healthy
normal individuals (n=6), all six acute MI patients with elevated levels of cTnT had
hypoxanthine levels above the 99th RLU percentile cut-off level. These results, although
having limited data (n=6 for each group), demonstrate the potential utility of using total
hypoxanthine (inosine plus hypoxanthine levels) as a biomarker of cardiac ischemic
conditions and the luminescence method as a rapid, simple and sensitive measurement
technique.
For evaluation of human plasma samples, the use of the HPLC-UV or microplate
luminometer both demonstrated the necessary sensitivity and specificity for determination
of inosine and hypoxanthine components in human plasma. However, each technique
offered certain specific advantages on its particular use. The HPLC-UV technique offers
complete separation and quantification of each component of interest without interferences
from endogenous uric acid, but the analytical run time of approximately 20 min may be too
long, if used in a hospital emergency department environment. The luminometer
technique offered a rapid analysis (<5 min), which is ideal for the emergency department
environment, but it does not individually measure inosine and hypoxanthine components,
and may have potential interferences (e.g. high plasma uric acids in gout patients or
individuals which may take antioxidant type GNC supplements such as ascorbic acid or
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polyphenols) that quench the luminescence emission from pholasin (i.e. signal suppression
with potential false negative results).
Since biomarker sensitivity and specificity are important parameters to evaluate, it
is important to briefly discuss them relative to this research project’s results. Total
hypoxanthine (inosine and hypoxanthine combined) is found endogenously in the body
from normal purine metabolism, thus making the specificity of using total hypoxanthine as
a biomarker of acute cardiac ischemia low, as it is not totally specific to heart tissue (as are
the cardiac troponins). However, under patient conditions of acute cardiac ischemia, the
increase in ATP catabolic by-products found in the bloodstream can certainly be attributed
to the heart cell mitochondria’s inability to produce sufficient amounts of ATP; thus
ultimately resulting in the efflux of ATP catabolic by-products inosine and hypoxanthine
out of the heart tissue and into the bloodstream. This higher concentration level of total
hypoxanthine (inosine and hypoxanthine) and the ED patient’s chief complaint of nontraumatic chest pain; potentially indicates an acute cardiac ischemic condition and warrants
immediate medical treatment. It should be mentioned that total hypoxanthine plasma
levels may also be significantly elevated from other potential ischemic conditions (e.g.
ischemic stroke, angina).
For biomarker sensitivity, luminescence technology is one of the most sensitive
analytical techniques currently available, and the results from Phase III demonstrated
sufficient sensitivity for total hypoxanthine in normal healthy individuals and cTnT
patients, even without plasma sample treatment (no extractions or preparation steps were
necessary). The recently FDA cleared IMA test for cardiac ischemia has the same
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biomarker properties (low specificity, high sensitivity), and was approved to be used in
conjunction with other test (ECG and cardiac troponin) to improve patient diagnostic
accuracy. Our proposed candidate biomarker may follow the same path as the FDA
cleared IMA biomarker; however it should be emphasized that one major difference
between these two biomarkers is the albumin that is modified from the ischemic heart
tissue is found in the bloodstream, and not effluxed from the cardiac tissue itself (thus the
low specificity). From the findings of this research, the total hypoxanthine levels that are
found elevated from acute cardiac ischemic conditions would be effluxed from the affected
heart issue into the bloodstream, thus potentially making hypoxanthine a more specific
biomarker than IMA for acute cardiac ischemia.
Some other potential sources of error in test results are shown in Table 14.
Individuals born with enzyme deficiencies (e.g. adenosine deaminase (ADA), purine
nucleoside phosphorylase) may cause erroneous results (e.g. false negative and false
positive results), however these individuals should also have immunological problems
which are associated with these enzyme deficiencies, and therefore communicated to
emergency department personnel as part of obtaining the patient medical history.
Kidney disease and kidney failure are two medical conditions which may lead to
potential errors in inosine and hypoxanthine test results. As elimination of most
substances from the blood stream is severely compromised in these patient populations,
even small polar components such as inosine and hypoxanthine may be retained in the
blood stream, leading to elevated blood concentrations and potential false positive results.
Kidney disease typically requires chronic treatments (e.g. medication) and individuals
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Table 14. Listing of enzyme deficiencies, food sources and medical conditions which
many contribute to errors in interpreting test results.

Potential Errors in Results

• ADA Deficiency - ↑ Adeno, ↓ Ino and ↓ Hypo

(causes immune problems) – potential false negative

• PNP Deficiency - ↑ Ino, ↓ Hypo (causes immune problems) –
potential false positive

• XO Deficiency - ↑ Xan, slight ↑

Hypo (may cause kidney problems)

• Kidney failure or disease
• Food sources containing purines – organ meats, mushrooms,
spinach, yeast, peas, beer

• Inosine – GNC (enhance athletic performance)
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having this disease are typically aware of their medical condition. However, kidney failure
may occur acutely from a traumatic event (e.g. acute kidney failure resulting from a ladder
fall), with the individual unaware of an acute kidney failure condition that can rapidly lead
to a significant buildup of waste products in their blood stream (thus leading to potential
erroneous test results). Individuals with XO deficiency or taking allopurinol (medication
commonly used for gout treatment), should have elevated levels of xanthine in the blood
potentially causing false positive results. Other sources of exogenous purines that may
cause potential errors in test results; would be from a high consumption of purine
containing food sources (e.g. organ meats, spinach, and beer) and the use of GNC
supplements (e.g. inosine advertised to enhance athletic performance).
In conclusion, it has been demonstrated using our animal model that inosine, a
potential biomarker of acute cardiac ischemia, was significantly effluxed from isolated
mouse hearts undergoing 20 min acute global ischemia (Phase I results). The significant
levels of effluxed inosine may best be explained by the acute cardiac ischemic event,
which causes ATP by-product catabolism and the formation and efflux of inosine by the
affected cardiac tissue (proof-of-biology). Subsequent work (Phase II), using human
plasma samples obtained from hospital emergency department patients with non-traumatic
chest pain, indicated elevated levels of inosine and significant levels of hypoxanthine
(inosine metabolism occurs immediately in red blood cells), thus supporting the results
from Phase I studies.
In Phase III and finishing the research project objectives, the development of a
potential clinical assay was achieved to rapidly measure inosine and hypoxanthine levels
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using only 20 µl of human plasma, in less than 5 minutes. As there are more than 10
medical conditions that may cause non-traumatic chest pain (e.g. angina, anxiety,
heartburn, acid reflux, etc.), it would benefit emergency medical service providers to have
additional biomarker(s) of acute cardiac ischemia and a rapid clinical diagnostic assay to
assist in patient diagnosis to either rule-in (RIMI) or rule-out (ROMI) acute MI. The
results of this work may one day help to answer the medical communities request for
additional biomarker(s) of acute cardiac ischemia, and ultimately lead to prompter
treatment for the millions of non-traumatic chest pain patients that visit hospital emergency
departments every year.
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For HPLC analysis, 100 µL of the perfusate samples were injected
neat onto a Synergi™Hydro-RP C18 column. A gradient consisting
of 0.05% TFA in deionized water:methanol (5% to 90%) was used
for component separation with diode array detection (DAD) used for
inosine quantification and LC/MS for inosine identity confirmation.
Area under the curve (AUC) computations were performed using the
trapezoidal rule.

Experiments were conducted to identify potential biomarkers from
perfusate of ICR outbred mouse hearts to which global ischemia
had been induced. The mice were anaesthetised, hearts removed,
and isolated for experiments using a Langendorff system. The
hearts were perfused using Krebs buffered solution (pH 7.4) which
contained 95%O2:5%CO2. Global cardiac ischemia was initiated by
adjusting the Krebs buffered solution to a zero flow rate for 20 min.
Upon heart reperfusion, samples of the perfusate were collected at
1, 3, 5, 10 and 20 min and frozen prior to HPLC analysis.

METHODS

When cardiac tissue is subjected to oxidative stress (e.g. cardiac
ischemia), less oxygen is available for cardiac mitochondria cells to
synthesize the required ATP for normal cardiac tissue function.
This results in cardiac cellular buildup of ATP metabolic byproducts (e.g. ADP, AMP) and activates normally dormant
enzymes (5´-nucleotidase, adenosine deaminase, purine
nucleoside phosphorylase) to catabolize ATP by-products to
substances such as adenosine, inosine, hypoxanthine, xanthine
and uric acid for biological elimination (Fig 1). Our research, using
the ICR outbred mouse model, indicates inosine may be a
potential endogenous biomarker of initial cardiac ischemia.

Each year in the US, 7-8 million patients are evaluated with nontraumatic chest pain. It is estimated that approximately 2-5% of
these patients are experiencing myocardial infarction but are
misdiagnosed and discharged. Emergency medical services
would benefit by having an early biomarker to differentiate initial
cardiac ischemia from other non-cardiac illnesses.
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Further research from our group will be performed on plasma samples
obtained from hospital admitted patients undergoing myocardial
infarction to determine if plasma levels of endogenous inosine are
significantly elevated during initial periods of cardiac oxidative stress. If
inosine plasma levels are found to be significantly elevated, this
biomarker may be useful to indicate the need for immediate medical
treatment, potentially improving patient outcomes.

These results, using the ICR mouse model, suggest that levels of
endogenous inosine found in human plasma during periods of cardiac
oxidative stress can serve as a potential biomarker for the onset of initial
cardiac ischemia.
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• Inosine and xanthine-like products (e.g. hypoxanthine, xanthine, uric
acid) were identified by retention time and DAD spectrum match and
were found to be increased 22 to 69 , >7 , ~3 and ~3 fold, respectively.
• Inosine levels were detected in all test (ischemic) samples and not in
the control (non-ischemic) samples (Table 1).
• Inosine levels were quantified using absorbance at 240 nm (Fig 2, RT
5.9 min) and LC/MS was used to confirm inosine (MW 268 Daltons)
identity in the mouse perfusate test (ischemic) samples.
• Heart % infarct size and % cardiac functional recovery was
determined for test and control mouse hearts (Table 1).
• A higher AUC for inosine was observed in test (ischemic) animals with
a lower %cardiac functional recovery than control animals, suggesting
a possible relationship between the two variables (Table 1).
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APPENDIX A

Poster presented at the 29th International Symposium on High Pressure Liquid Phase

Separations and Related Techniques (Stockholm, Sweden, June 2005).

Upon heart reperfusion, samples of the KBS perfusate were
collected at 1, 3, 5, 10 and 20 min and frozen prior to analysis by
HPLC. 50 µL of the collected samples were injected for HPLC
analysis using chromatography conditions consisting of a Onyx™
monolithic C18 column, HPLC mobile phase of 0.05% TFA in
deionized water/methanol (5% to 90% gradient) and diode array
detection. Area under the curve (AUC) computations were
performed using the trapezoidal rule.

Further investigations were conducted to measure inosine levels
from perfusate of ICR outbred mouse hearts to which global
ischemia had been induced. The mice were anesthetized with
sodium pentobarbital, hearts were surgically removed and isolated
for experiments using a Langendorff system. The hearts were
perfused using either KBS (non-SA) or a modified KBS (1 mM SA)
purged with 95%O2:5%CO2 (pH 7.4). Global cardiac ischemia was
initiated by adjusting the KBS to a zero flow rate for 20 min.
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• Inosine and hypoxanthine levels were quantified using DAD
absorbance at 250 nm (Fig 2) and LC/MS was used to confirm
hypoxanthine (RT 4.9 min) and inosine (RT 6.9 min) identity in the
mouse perfusate test (ischemic, 0401.D) versus control (0301.D)
samples.
• Inosine levels (Table 1) found in the perfusate samples from ischemic
hearts subjected to 1 mM SA (n=4) were significantly higher (p<0.05) as
compared to non-SA (n=6) ischemic hearts (mean AUC inosine 8514 ±
3284 SEM versus 1437 ± 348 SEM, respectively).
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In our studies, SA was initially used to study the generation of
hydroxyl free radical formation during global ischemia-reperfusion in
isolated mouse hearts; however, we observed that inosine (a
previously proposed biomarker of initial cardiac ischemia) levels were
elevated following ischemic conditions in hearts perfused with
modified Krebs buffered solution (1 mM SA) relative to non-SA Krebs
buffered solution (KBS).
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Each year worldwide, approximately 32 million individuals experience
myocardial infarction. Emergency medical services to patients
experiencing myocardial infarction typically include treatment using
aspirin® (acetyl salicylic acid, ASA) to reduce platelet formation at the
site of cardiac thrombosis. Salicylic acid (SA) is an aspirin®
metabolite which has been shown to react with hydroxyl free radicals
(Fig 1) generated under conditions of cardiac oxidative stress to form
stable reaction products that can be measured quantitatively using
HPLC.
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Our results indirectly support a recently published report
demonstrating salicylic acid’s role in decoupling cardiac mitochondrial
respiration (Nulton-Persson et al., J. Cardiovasc. Pharmacol. 44(5)
2004). Further research will be performed to determine if a dose
response relationship exist between SA concentration and resulting
inosine levels during cardiac ischemia-reperfusion.

These results suggest that 1 mM SA negatively affects ischemic
myocytes undergoing nucleotide purine catabolism and potentiates
(~3x) ATP degradative products (e.g. inosine, hypoxanthine).
However, evaluation of the enzymatic conversion of inosine to
hypoxanthine ratio (Table 2) indicates that SA does not inhibit cardiac
muscle enzyme purine nucleotide phosphorylase but instead affects
an upstream event in the cellular respiration pathway.
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APPENDIX B

Poster presented at Pittcon 2006 Analytical Exposition (Orlando, Florida, March 2006).
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APPENDIX C
Virginia Commonwealth University (VCU) IRB Application and Approval Forms.
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Farthing IRB #4336 Research Synopsis
I.

Title: Evaluation of Potential Biomarker(s) in Human Plasma for Initial Cardiac

Ischemia
II.

Investigators: Dr. Domenic Sica M.D., Don Farthing (Graduate Student)

III.

Hypothesis: Our hypothesis is that endogenous inosine (purine) may be present in

human plasma from the catabolism of ATP in ischemic heart tissue. Therefore, inosine
may be a potential biomarker of initial human cardiac ischemia prior to heart tissue
necrosis (protein biomarkers released).
IV.

Specific Aims: Our specific aim of this research is to determine if inosine is present

in plasma samples from patients that were admitted for treatment of myocardial infarction
(MI). If inosine is present in patients diagnosed and treated for MI (test) and is not present
in plasma samples from patients without MI (control), we will pursue developing a
possible point-of-care technique to determine inosine levels in plasma.
V.

Background and Significance: Each year in the US, approximately 7-8 million

patients arrive with non-traumatic chest pain to hospital emergency rooms. Medical
personnel are challenged to properly diagnose and treat these patients. It is estimated that
approximately 2-5% of these patients are experiencing myocardial infarction, but due to
misdiagnosis, they are incorrectly discharged leading to medical malpractice. Thus,
emergency medical services to patients would benefit by having a biomarker to help
differentiate initial cardiac ischemic conditions from other noncardiac illnesses, which also
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may cause chest pain (e.g. GERD, heartburn, asthma, gallstones, pneumonia, and
pancreatitis).
VI.

Preliminary Progress/Data Report: Initial animal experiments were performed

during 2003-2004 at VCU (Dr. Lei Xi, IACUC #0405-2957, Dept. of Internal Medicine,
Div. of Cardiology) using the ICR outbred mouse strain. The mice were anaesthetised,
hearts surgically removed and isolated for experiments using a Langendorff system. The
hearts were perfused using Krebs buffered solution at pH 7.4 and contained
95%O2:5%CO2. Global cardiac ischemia was initiated by adjusting the Krebs solution to a
zero flow rate for 20 min. Upon heart reperfusion with 95%O2:5%CO2, samples of Krebs
solution eluant from the heart were collected at predetermined times and frozen prior to
HPLC analysis. For HPLC analysis, 100 µL of the collected sample was injected neat,
using chromatography conditions consisting of a C18 reversed phase column, gradient
mobile phase and diode array detection.
VII.

Preliminary animal test results from above initial research indicated that inosine

may be a potential biomarker indicative of initial mouse cardiac ischemia. Inosine and
xanthine-like products (e.g. hypoxanthine, xanthine and uric acid) were found at higher
levels in mice subjected to global cardiac ischemia versus non-ischemic conditions. These
results can be explained by ischemic myocytes undergoing nucleotide purine catabolism in
the absence of oxygen, which activates normally dormant cellular enzymes and generates
degradative products (e.g. adenosine, inosine, hypoxanthine and xanthine) from the
breakdown of ATP.
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VIII. Research Method & Design: As part of my Ph.D. thesis (D. Farthing, MCV
graduate student, Dept. of Pharmaceutics), I am requesting IRB approval to obtain existing
plasma samples from cardiovascular (ischemic) diseased patients that have received
treatment from VCU Medical Center Hospitals. These patients were diagnosed with
myocardial infarction and subsequently treated at VCU Medical Center Hospitals. All
plasma samples (25 from non-ischemic patients (controls) and 25 from ischemic patients
(tests)) will be obtained from patients previously admitted for medical treatment. The
plasma samples (frozen and obtained from the Dept. of Clinical Chemistry) will be
stripped of any patient information on the sample tubes for compliance with current patient
privacy laws (HIPPA). The samples will be coded as control or test samples (e.g.
numbered 1-25) by Dept. of Clinical Chemistry personnel who have been trained on
HIPPA regulations. Human plasma samples obtained will be extracted and evaluated for
inosine levels using a developed HPLC method at an MCV laboratory (Dr. Domenic Sica,
Dept. of Internal Medicine, Division of Clinical Pharmacology). The results and
interpretation of these experiments will likely be submitted for publication in a scientific
journal (e.g. Clinical Chemistry) and used as part of D. Farthing’s Ph.D. thesis. I am
requesting an expedited review from Federal Regulations for the Protection of Human
Subjects (45 CFR 46) based on the following reason. All plasma samples obtained will be
existing samples that were initially used for patient diagnostic information.
IX. Statistical Analysis: Statistical analysis is not applicable as inosine from the pateint’s
ischemic cardiac tissue will either be present or not present in the plasma samples. The
reason for this all or nothing expectation is that the biological half-life of inosine has been
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published to be approximately one minute in humans so it may be completely metabolised
and not detected. However, if detected, it may indicate that inosine is a potential
biomarker of initial human cardiac ischemia prior to heart tissue necrosis.
X.

Data and Safety Monitoring: Not applicable

XI.

Human Subjects Instructions: Not applicable
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APPENDIX D
Additional plasma purchased from ProMedDx and evaluated using HPLC.
Sample
Type
Ctrl-1
Ctrl-1
Ctrl-2
Ctrl-2
Ctrl-3
Ctrl-3
Ctrl-4
Ctrl-4
Ctrl-5
Ctrl-5
Ctrl-6
Ctrl-6
Ctrl-7
Ctrl-7
Ctrl-8
Ctrl-8
Ctrl-9
Ctrl-9
Ctrl-10
Ctrl-10
HT-1
HT-1
HT-2
HT-2
HT-3
HT-3
HT-4
HT-4

Matrix
Plasma (Li
Heparin)
Serum (no gel)
Plasma (Li
Heparin)
Serum (no gel)
Plasma (Li
Heparin)
Serum (no gel)
Plasma (Li
Heparin)
Serum (no gel)
Plasma (Li
Heparin)
Serum (no gel)
Plasma (Li
Heparin)
Serum (no gel)
Plasma (Li
Heparin)
Serum (no gel)
Plasma (Li
Heparin)
Serum (no gel)
Plasma (Li
Heparin)
Serum (no gel)
Plasma (Li
Heparin)
Serum (no gel)
Plasma (Li
Heparin)
Serum SST
Plasma (Li
Heparin)
Serum SST
Plasma (Li
Heparin)
Serum SST
Plasma (Li
Heparin)

HT-5

Serum SST
Plasma (Li
Heparin)

HT-5

Serum SST

ProMedDx
#

Gender

Age

10372009

M

51

10372011

10372018

10372020

10372026

10372027

10372028

10372030

10372032

10372035

10417810

10417811

10417814

10425962

10425963

M

M

M

M

M

M

M

M

M

F

M

F

F

F

50

20

34

49

18

38

38

43

38

25

44

30

43

37

Ino

Hypo

[µM]

[µM]

Comments
Normals (PromedDx)

<0.9

<1.8

<0.9

<1.8

"

<0.9

1.5

"

<0.9

1.3

"

<0.9

2.2

"

<0.9

2.1

"

<0.9

1.9

"

<0.9

1.9

"

<0.9

1.5

"

<0.9

2.0

"

<0.9

3.4

"

<0.9

4.6

"

<0.9

1.3

"

<0.9

1.3

"

<0.9

<1.8

"

<0.9

<1.8

"

<0.9

1.5

"

<0.9

1.5

"

<0.9

<1.8

"

<0.9

<1.8

"

<0.9

2.2

0.7

7.8

Hypertension (PromedDx)
Patients

<0.9

2.9

"

0.8

25.8

"

<0.9

2.0

"

3.6

12.5

"

<0.9

7.3

"

<0.9

25.8

"

<0.9

1.1

"

<0.9

3.8

"

BP 210/105, Hct

BP 150/104, Glipizide

BP 180/98, Tenormin

BP 150/110, Tenormin

BP 160/102, Tenormin
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HT-6
HT-6
HT-7
HT-7
HT-8
HT-8
HT-9
HT-9
HT-10
HT-10
cTnI-1
cTnI-1
cTnI-2
cTnI-2
cTnI-3
cTnI-3
cTnI-4
cTnI-4
cTnI-5
cTnI-5
cTnI-6
cTnI-6
cTnI-7
cTnI-7
cTnI-8
cTnI-8
cTnI-9
cTnI-9

Plasma (Li
Heparin)
Serum SST
Plasma (Li
Heparin)
Serum SST
Plasma (Li
Heparin)
Serum SST
Plasma (Li
Heparin)
Serum SST
Plasma (Li
Heparin)
Serum SST
Plasma (Li
Heparin)
Serum SST
Plasma (Li
Heparin)
Serum SST
Plasma (Li
Heparin)
Serum SST
Plasma (Li
Heparin)
Serum SST
Plasma (Li
Heparin)
Serum SST
Plasma (Li
Heparin)
Serum SST
Plasma (Li
Heparin)
Serum SST
Plasma (Li
Heparin)
Serum SST
Plasma (Li
Heparin)

cTnI-10

Serum SST
Plasma (Li
Heparin)

cTnI-10

Serum SST

10425964

10425965

10425966

10425968

10425971

11075181

11075182

11075183

11075186

11075187

11075189

11075193

11107700

11109491

11109492

F

F

M

F

F

F

M

F

F

F

F

F

F

M

F

52

39

29

45

25

86

86

71

74

90

59

54

49

90

54

<0.9

2.5

"

<0.9

11.4

"

<0.9

5.9

"

<0.9

30.0

"

<0.9

1.3

"

0.7

12.8

"

<0.9

1.4

"

3.6

14.9

"

<0.9

0.8

"

2.4

13.7

"

3.6

21.7

0.9

9.1

"

5.3

3.3

"

4.4

6.3

"

<0.9

7.2

"

<0.9

7.2

"

<0.9

6.2

"

<0.9

7.4

"

1.0

7.3

"

0.8

13.7

"

<0.9

9.7

"

2.0

9.2

"

<0.9

4.6

"

1.2

19.8

"

<0.9

33.6

"

<0.9

10.9

"

<0.9

12.7

"

<0.9

4.1

"

<0.9

31.2

"

<0.9

14.3

"

BP 165/103, Hct

BP 175/82, Hct

BP 160/89, Lotensin

BP 148/98, Hct

BP 140/98, Hct and Lisinopril

MI Patients (PromedDx)
cTnI 0.4 ug/L

0.5

0.8

0.4

0.6

0.5

0.9

0.6

31.9

1.1

Notes:
1. ProMedDX (Norton, MA), a FDA registered biorepository with all samples acquired following IRB approval.
2. Ino= Inosine, Hypo= hypoxanthine, HT = hypertension, cTnI = cardiac tropoinin I.
3. Plasma and serum samples evaluated on same analytical run using calibration curve (DI standards) and controls (plasma).
4. HT and cTnI samples from same hospital, using SST tubes (gel) and following package insert (clotting and spin time, centrifugal force
etc). (per PromedDx).
5. Controls from normal donor collection center using red top serum tubes (no gel) per PromedDx.
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Professional Training / Seminars
ACS Courses – GLP; QA/QC for the Laboratory; Troubleshooting HPLC systems;
Practical LC/MS, Analysis and Interpretation of MS.
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Pittcon Courses – Computer and Equipment Validation; Fast GC; ISO Guidelines for
Uncertainty Calculations; Online Chemical Searching; Sampling of Solids, Gases, and
Liquids; Statistics Review; Headspace Theory and Practical; Sample Preparations; HPLC
Method Development for LC/MS.
ASMS Courses – LC/MS.
Thermo Nicolet – FT-IR Operation and Interpretation; XRF Operation and Interpreation.
ISSX – Toxicology.
Gerstel – Headspace; Thermal Desorption; Twister.
Agilent – LC/MS Lab on a Chip; 5973 Agilent MSD Troubleshooting; Macro
Programming.
PBA Courses – Pharmacokinetics for Chemist, Metabonomics: Principles and Practices.
Biomarkers – Biomarker assay development and validation.
Professional Memberships and Activities
American Chemical Society – since 1996
ACS Chemical Toxicology – since 1996
Journal of Chromatography B – manuscript reviewer since 2000
Chromatographia – manuscript reviewer since 2006
Member of Philip Morris R&D Emergency Response Team (hazmat, fire, medical) –
1999-2006
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